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Surfactant proteins, SP-A and SP-D, are collagen-containing calcium-dependent (C-
type) lectins, called, collectins. Their primary structure has four regions: a cysteine-
linked N- terminal region involved in multimerization, a collagen region composed of 
Gly-X-Y repeats, coiled-coil neck region, and the C-terminal carbohydrate 
recognition domains (CRD) or C-type lectin domain. SP-A looks like a bouquet, while 
SP-D is a cruciform- like structure, with four arms of equal length. SP-A and SP-D 
have been shown to act as innate immune molecules at pulmonary as well as extra-
pulmonary sites by binding to pathogens, allergens and apoptotic/necrotic cells via 
their CRD region. SP-A and SP-D can induce pathogen neutralization and enhanced 
phagocytosis. In addition, SP-A and SP-D can interact via CRDs with allergens and 
dampen allergic reaction in vitro and in vivo.  
This thesis examines in vitro interaction of a recombinant fragment of human SP-D 
containing neck and CRD regions (rhSP-D) with IAV and Aspergillus fumigatus, in 
addition to characterizing a dichotomy of the effects of SP-A and SP-D on dendritic 
cells in an attempt to explain how SP-A and SP-D modulate DC functions 
differentially. Experiments involving interaction of rhSP-D with IAV pandemic strain 
show that it can be a restrictive factor against the virus, in addition to modulating 
immune response by a macrophage cell line. The rhSP-D can have anti-A. fumigatus 
effect directly and indirectly in the context of pathogen as well as allergen. A 
comparison has been made between two recombinant fragments of SP-D that have 
been expressed with and without 8 Gly-X-Y repeats for their fungistatic properties. 
The effects of SP-A and SP-D on cultured DC maturation, and effector cytokine and 
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Our immune system plays a vital role in our healthy status. Immune system has two 
main arms, innate and adaptive immune systems. Innate immunity is the first line of 
defence against any microbial attack (Medzhitov and Janeway, 2002). The average 
person inhales about 10,000 litres of gas per day, and this gas is laden with a plenty 
of bacteria, viruses, oxidants, pollutants and allergens (Wright, 2004).  The lung help 
maintain its sterility through several mechanisms. The innate immune response is 
very crucial in limiting the early replication and spread of pathogens, which may 
involve opsonins, such as immunoglobulin and complement; and phagocytic cells 
such as alveolar macrophages, and neutrophils (Wright, 2004). The innate immune 
system is designed towards recognition of pathogenic non-self. 
2.1 1.1. Pattern recognition receptors (PRRs) interaction 
with Pathogen associated molecular patterns (PAMPs)  
The innate immune system recognizes conserved motifs in pathogens called 
“pathogen- associated molecular patterns” (PAMP) (Barton and Medzhitov, 2002; 
Medzhitov and Janeway, 2002). Pathogens can be identified as non-self through 
PAMP by pathogen recognition receptors (PRRs), which can be humoral and cellular 
receptors (Beutler, 2004). NOD like receptors are intracellular while collectins, and 
pentraxins are humoral PRRs (Taylor, Gordon and Martinez-Pomares, 2005; 
Medzhitov and Janeway, 2002).The classical short pentraxins (CRP) and serum 
amyloid P (SAP) component circulate as pentamers in human plasma. The long 
pentraxins include PTX3, PTX4 and neuronal pentraxins (Bottazzi et al, 2010 ; 
Deban et al, 2011). Toll-like receptors (TLRs) are cell surface sensor PRRs whereas 
there are also phagocytic/endocytic receptors such as scavenger receptors and 
lectins (Mukhopadhyay, Pluddemann and Gordon, 2009). TLRs have an essential 
role in the innate recognition of PAMPs and in triggering acquired immunity (Akira, 
Takeda and Kaisho, 2001; Aderem and Ulevitch, 2000; Barton and Medzhitov, 2002; 
Medzhitov and Janeway, 2002). TLR4 recognizes lipopolysaccharide (LPS), 
whereas TLR2 recognizes various fungal, Gram-positive, and mycobacterial 
components (Flo et al, 2000;Takeuchi, Hoshino and Akira, 2000; Aliprantis et al, 
1999; Brightbill et al, 1999; Hoshino et al, 1999; Lien et al, 1999; Means et al, 1999; 
Takeuchi et al, 1999; Underhill et al, 1999a; Underhill et al, 1999c).  
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2.2 1.2. Link between innate and adaptive immunity  
The adaptive immune system is a highly complex system found in vertebrates 
(Takeda, Kaisho and Akira, 2003 ;). TLRs contain a characteristic leucine- rich 
repeat (LRR) domain in their extracellular domain and a TIR domain in their 
intracellular domain (Takeda, Kaisho and Akira, 2003). The translation of innate to 
adaptive immune response requires that antigens be captured and processed prior 
to the information of ligands for the T cell receptor (Steinman and Hemmi, 2006). 
The most important player in this story is dendritic cell (DC) as antigen presenting 
cells (APCs), since they can capture antigens in peripheral tissue and migrate to 
secondary lymphoid organs where they acquire the ability to stimulate naïve T cells 
(Cella et al, 1997; Banchereau and Steinman, 1998; Mellman et al, 2014). DCs load 
pathogen derived peptides onto MHC class I or class II molecules and present on 
the cell surface to their cognate T cells which are then induced to clonally proliferate 
and mount cytotoxic or helper T cell functions (Mellman and Steinman, 2001). DCs 
can also express ligands such as CD80 and CD86 that bind to costimulatory 
molecules on T cells (signal 2); aiding MHC-specific-T cell receptors (signal 1). In 
addition to, DCs produce cytokines such as IL-12, which are essential to stimulate T-
cells (Trombetta and Mellman, 2005).  
Signal 1 alone promotes naïve T-cell inactivation by anergy, deletion or co-option 
into a regulatory cell fate, thus to tolerance (Sousa Vde et al, 2006). Signal 2 
together with signal 1 induces immune response (Keir and Sharpe, 2005) (Domowicz 
et al, 2003). Subsequent cytokine response can determine T cell differentiation into 
to helper T cells (Th1), or cytotoxic T cells (Th2) (Curtsinger, Lins and Mescher, 
2003; Kalinski et al, 1999). IL -12, for instance, promotes Th1 cells or CTL 
development (Trinchieri, 2003). 
Interferons are produced rapidly in response to infection. They play a key role in 
innate immunity and promote adaptive immune responses. IFN-γ, which is secreted 
by Th1 cells, can modulate both innate and adaptive immunity (Billiau and Matthys, 
2009). IFN-γ activates macrophages, stimulates natural killer cells, B cells as well as 
endothelial cells, and once endothelial cells were activated by IFN-γ it promotes 
expression of adhesion molecules. Macrophages activated by IFN-γ produce pro-
inflammatory cytokines like TNF-α and IL-6, oxygen radicals, and metalloproteinase 
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(MPPs) (Voloshyna et al, 2013) . On the other hand, IFN-α stimulates the expression 
of MHC molecules (Takaoka and Yanai, 2006; Brassard, Grace and Bordens, 2002). 
IFN-α also enhances expression of IFN-γ in NK, CD4+ and CD8+ T cells, and 
upregulates TNF-α (Brassard, Grace and Bordens, 2002), IL-18R (Sareneva, 
Julkunen and Matikainen, 2000; Eriksen et al, 2009; Rogge et al, 1997; Rogge et al, 
1997; Dickensheets et al, 1999; Pene et al, 1988). Finally, IFN-α affects both up- and 
down regulation of IL-4R signalling in T cells (Eriksen et al, 2004; Hansen et al., 
2011). LPS can induce the production of IL-27(Schnurr et al, 2005; Pflanz et al, 
2002), which signals through activation of STAT1 and STAT3 (Guzzo et al, 2010; 
Pflanz et al, 2004; Pflanz et al, 2002). In addition, IL-27 functions to promote 
differentiation of naïve Th cells into Th1 cells (Lucas et al, 2003; Pflanz et al, 2002). 
IL-27 also activates monocytic cells, which includes upregulation of pro-inflammatory 
cytokine and chemokine production (Guzzo et al, 2010; Kalliolias and Ivashkiv, 
2008). 
 
Figure 1.1. Antigen capture and presentation by dendritic cells (DCs). DCs are the most potent 
antigen capturing and presenting immune cells at the bridging sentinel of the innate and adaptive 
immunity. Following the interaction of immature DCs with pathogens at the site of infection or foreign 
non-self, the ingested material is brought to lymph draining by immature DCs where they mature and 
present the antigenic peptides to the T cells via MHC Class II molecules, triggering the effector 




2.3 1.3. Complement system 
The complement system is made up of a large number of plasma proteins as well as 
membrane-bound receptors and regulators, which have the ability to react with one 
another to attack the pathogens and induce a series of inflammatory responses 
(Shastri, Bonifati and Kishore, 2013). The three pathways of the complement system 
converge on the generation of C3 convertase, and all ending up with the generation 
of the same set of effector molecules, membrane attack complex (MAC) (figure 1.2) 
(Shastri, Bonifati and Kishore, 2013). The three initiating pathways are called (i) 
classical pathway which is mostly antibody mediated (C1q being the first 
subcomponent) and is activated by C1 complex (C1q-C1r-C1s). The classical 
pathway is activated by immune complexes containing IgG and IgM, which bind to 
microbial surfaces (Kishore et al, 1998); (ii) Alternative pathway (AP) which is 
activated spontaneously involving low-level hydrolysis of C3 to C3 (H20). The 
alternative pathway is dependent upon a spontaneous C3 binding and activation into 
C3b through thioester activation on charged surface. Properdin stabilizes C3 
convertase, thus acting an up-regulator of alternative pathway; (iii) Lectin pathway 
has its recognition molecule called mannan-binding lectin (MBL) whose binding to 
carbohydrate PAMPs is followed by binding of MBL-associated serine protease 2 
(MASP-2) to MBL (Jensenius et al, 2003)Thiel and Gadjeva, 2009). Complement 
components are mostly synthesized by liver. However, there is plenty of evidence in 
literature suggestive of local synthesis of complement protein by immune cells at the 
side of infection, injury, inflammation, and homeostasis (Nayak et al, 2010; Nayak et 
al, 2012). 
Complement cascade can be activated by any of these three pathways, leading to 
the following: (1) Activation of C3b, which binds to microbes and opsonizes them for 
phagocytosis. (2) Generation of C3a and C5a, which are potent anaphylatoxins, 
capable of cellular infiltration at the site of infection. 3) Activation of C5 through C9, 
the latter component of which  forms membrane attack complex (MAC) that can lyse 







Figure 1.2 Complement pathways. C1q initiates the complement classical pathway. In the lectin 
pathway, the recognition proteins include mannan-binding lectin (MBL) that mainly binds to vicinal 
diols on sugars such as mannose, fucose or glucosamine. After C1q is bound to its targets, proteases 
C1r and C1s are activated (or for MBL, MBL-associated serine proteases, MASP-1, 2 and 3, are 
activated). This then activates complement proteins C4 and C2 forming a C3 convertase (C4b2a), 
which cleaves C3 to form C3b that then binds to the target surface. C3b and its breakdown products, 
iC3b and C3dg, interact with C3 receptors on phagocytic and other cells.  C3b is also is a binding site 
for C5, which is activated by the same protease which cleaves C3, and then forms a complex with C6, 
C7, C8 and C9 (C5-9), called membrane attack complex (MAC), which disrupts the lipid bilayer of 
cells. The activation of the complement alternative pathway involves a constant slow hydrolysis of 
C3 in solution, which forms C3(H2O), and alters the shape of the protein. This conformational change 
allows the formation of a complex between factor B and C3(H2O), which allows factor D to cleave the 
bound factor B into Ba, which is removed and Bb, which remains bound. C3(H2O)Bb  is a protease 
which cleaves more C3 to form C3b, which can bind to target surfaces, and form a complex with 
factor B, which is converted to C3bBb, by factor D, as above. This leads to coating of the target 
particle with C3bBb, which is a homologue of the classical pathway C3 convertase, C4b2a. C3bBb, 
the alternative pathway C3 convertase, can be further stabilized by properdin (factor P) to C3bBbP. 
This complex is an enzyme able to generate more C3b to bind to targets. This is an amplification 
mechanism in order to increase turnover of C3 and coating of targets with C3b.  To avoid consuming 
all available C3, the amplification mechanism needs to be balanced by down regulators: Factor H 
binds to C3b inhibiting C3 convertase formation, and together with factor I it cleaves C3b to iC3b, 




2.4 1.4. Collectins 
Two groups of the C-type lectin family are important components of the innate 
immune response. The first is collectins (Collagen containing lectins) which are 
soluble proteins and mediate pathogen neutralization (Crouch and Wright, 2001). 
The second is the macrophage mannose receptor, which is a cell-surface protein 
that leads directly to phagocytosis of microorganisms (Weis, Taylor and Drickamer, 
1998) and secret ion of pro-inflammatory cytokines and chemokines (Ozinsky et al, 
2000).  
Nine types of collectins have been reported so far: MBL, lung surfactant protein A 
(SP-A) and D (SP-D), bovine conglutinin, collectin-43 (CL-43), and collectin- 46 (CL-
46) (Epstein et al., 1996; Holmskov et al., 1994; Hoppe and Reid, 1994). Another set 
of collectins have also been found, collectin liver -1 (CL- L1), and collectin placenta 1 
(CL- P1). CL-43, CL-46 and conglutinin are found in bovine. 
The subunit structure of collectins includes an N-terminus linking region, a triple-
helical collagen domain, a coiled-coil neck region, and a C-type lectin domain, also 
called a carbohydrate recognition domain (CRD). Recognition of specific ligands of 
microorganism is mediated by CRD in presence of calcium (Weis, Drickamer and 
Hendrickson, 1992; Weis et al, 1991) (Lee et al, 1991). This interaction often results 
in enhanced phagocytosis and clearance of the pathogen in vitro (Vaandrager and 
van Golde, 2000). 
Pulmonary surfactant is comprised of phospholipids and proteins, including four 
surfactant proteins (SP): SP-A, SP-B, SP-C, and SP-D (Possmayer, 1988). The most 
abundant of the surfactant- associated protein is SP-A, while SP-D is present at 
about tenth the concentration of SP-A (Wright, 1997). SP-A and SP-D, interact with 
carbohydrate structures on the surface of a pathogen such as virus, bacteria, or 
fungi through its CRD and then enhancing phagocytosis and killing by myeloid cells 
(Reid, 1998; Wright, 1997). Surfactant proteins are synthesized and secreted into 
lung airspaces by type II pneumocytes and Clara cells (Haller et al., 1992; Voorhout 
et al, 1992). SP-A and SP-D comprise of higher oligomers: hexameric (boqute like 
structure) or tetrameric (cruci-form like structure, with four arms of equal length) 
molecules, having 18 or 12 CRDs, as found in SP-A and SP-D, respectively (Lu, 







Figure 1.3 The structures of collectins. The primary structure of collectins includes an N-terminal 
cysteine rich region, a triple-helical collagen region, a coiled-coil neck region, and a C-terminal C-type 
ectin domain or carbohydrate recognition domain (CRD) which is homotrimeric in organisation. Six of 
these primary units combine to give the SP-A its classical bouquet shaped 18-mer structures, similar 
to complement proteins C1q and MBL. Three polypeptide chains combine to form a trimeric structure 
that combines with another three similar structures to give SP-D its characteristic cruciform structure. 




Figure 1.4 Innate immune mechanisms in the lungs.  Lung is constantly exposed to a range of 
toxic materials that include pathogens and allergens, capable of inducing pro-inflammatory immune 
response. SP-A and SP-D, which are secreted by type II epithelial and Clara cells in the lungs, appear 
to have a protective and homeostatic function. They can be potent opsonins for pathogens and recruit 
alveolar macrophages for their enhanced clearance, a function similar to complement proteins 




Figure 1.5 Functions assigned to the different parts of the SP-A and SP-D molecules. Different 
regions of SP-A and SP-D have well-defined functions. The N-terminal cysteine rich region is 
responsible for cross-linking monomers leading to higher order oligomers. The triple-helical collagen 
region is the trimerising area that stabilizes the overall structure of collectins. The alpha-helical coiled-
coil neck region is considered the nucleation center for the trimerization of the single subunit. The 
homotrimeric CRD region is the pattern recognition or ligand-binding region of the collectins. Most of 
the ligands are recognized via the CRD region with few exceptions. The collagen region is also 
responsible for the protein interaction with their cognate receptor complex of calreticulin-CD91 




                                                    
Figure 1.6 X-ray crystal structure of rhSP-D showing three subunits representing CRD 
domains. The three-dimensional structure of trimeric recombinant neck–CRD fragments of human 
SP-D (rhSP-D) when viewed perpendicular to the molecular three-fold axis. The three subunits have 
been designated A, B and C. The maltose-bound rhSP-D trimer shows the bound maltose and the 
three calcium ions.The tightly packed neck region appears to stabilise the CRD region, consistent with 
the evidence that when the CRD region is expressed heterologously without neck region, the 
recombinant protein falls off as a monomer, highlighting the key role played by the neck region 












Figure 1.7 Crystal structures of trimeric rhSP-D and rhSP-A showing bound calcium and maltose  
(Shrive. 2009; Kishore. 2006). Three-dimensional structures of trimeric recombinant neck–CRD 
fragments of human SP-D (left) and rat SP-A (right). (a) Neck–CRD trimeric fragment viewed 
perpendicular to the molecular three-fold axis. The maltose-bound rhSP-D trimer shows the bound 
maltose and the three calcium ions. (b) The coordination of the calcium ion Ca1 and bound maltose in 








2.5 1.5. The Immunological importance of SP-A and SP-D 
SP-A and SP-D are soluble PRRs which can interact with glycoconjugates and lipids 
on the microbial surfaces via their CRDs (van Iwaarden et al, 1992; Weis, Taylor and 
Drickamer, 1998). These collectins bind mannose and glucose residues more 
strongly (Kishore and Reid, 2001 ; Holmskov, Thiel and Jensenius, 2003). SP-A and 
SP-D interact with a wide range of pathogenic viruses, bacteria and fungi and cause 
agglutination, enhancement of phagocytosis and killing (Wright, 2005). In addition, 
SP-A and SP-D can also alter cytokine and chemokine levels at the site of infection. 
2.6 1.6. Interaction and clearance of viral, bacterial and 
fungal pathogens 
The interaction of SP-A and SP-D with different strains of Influenza A virus (IAV) 
involves binding hemagglutinin (HA), neuraminidase (NA), and their levels of 
glycosylation. The presence of sialic acid residues on the CRD surface of SP-A also 
helps in targeting IAV (Benne et al, 1995). This interaction causes agglutination, and 
infection inhibition, followed by alveolar macrophage and neutrophil mediated 
elimination of virus. Co-incubation of IAV with SP-A enhances production of H2O2 by 
neutrophils (Hartshorn et al, 1997). SP-D also induces IAV aggregation, inhibits HA 
and neuraminidase activities, and neutralizes IAV (Hartshorn et al, 1996 ; Hawgood 
et al., 2004; Reading et al., 1997). IAV, pre-incubated with SP-D, also enhances 
superoxidative burst. SP-A binds respiratory syncytial virus (RSV), and enhances 
phagocytosis by PBMCs and alveolar macrophage (Ghildyal et al, 1999), and leads 
to TNF-α production (Barr et al, 2000; Hickling et al, 1999) . 
SP-A and SP-D lectin domains bind a variety of Gram-positive and -negative 
bacteria (Hartshorn et al., 1994; Van Iwaarden et al., 1994; Hartshorn et al, 1998), 
enhancing phagocytosis and killing. SP-A and SP-D bind to Staphylococcus aureus 
(Geertsma et al, 1994), Pseudomonas aeruginosa, and Escherichia coli J5 
(containing O-antigen deficient rough LPS) (Van Iwaarden et al, 1994),  
Mycobacterium tuberculosis (Pasula et al, 1997; Gaynor et al, 1995), Streptococcous 
pneumonia, Hemophilus influenzae (McNeely and Coonrod, 1994), Klebsiella 
pneumoniae (Kabha et al, 1997), and Bacillus Calmette Guerin (BCG) (Weikert et al, 
1997), causing agglutination and phagocytosis by macrophages (Pikaar et al, 1995 
;Sahly et al, 2002; Van Iwaarden et al, 1994), Bacillus subtilis, and S. aureus (van de 
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Wetering et al., 2001), purified LPS from P. aeruginosa and E. coli (Kishore et al, 
1996), Mycobacterium tuberculosis (Ferguson et al, 1999; Pasula et al, 1997; 
Gaynor et al, 1995), and Mycoplasma pulmonis (Hickman-Davis et al., 2001). 
SP-D interacts with Saccharomyces cerevisiae via its CRD, (Allen, Voelker and 
Mason, 2001) and to the β-glucans of Pneumocystis. SP-D binds to Candida 
albicans and inhibits pseudohyphal/hyphal growth (van Rozendaal et al, 2000). SP-A 
suppresses pro-inflammatory TNF-, IL-1, MIP-, and MCP-1 production by 
alveolar macrophage (Rosseau et al, 1999; Rosseau et al, 1997). SP-A and SP-D 
cluster Pneumocystis carinii via gpA (glycoprotein 120) which is present on 
expressed cysts and trophozoites (Zimmerman et al, 1992). They agglutinate the 
pathogenic Cryptococcus neoformans (Schelenz et al, 1995) as well as Aspergillus 
fumigatus conidia; this enhances their phagocytosis and killing by human alveolar 
macrophages and circulating neutrophils (Madan et al, 1997a). Intranasal 
administration of SP-D and rhSP-D in an immunosuppressed murine model of 
invasive pulmonary aspergillosis (IPA) rescued about 80% of the mice, while SP-A 
did not have a significant effect on IPA mice survival (Madan et al, 2001). The 
protective effects were consistent with reduced colony forming units, lack of hyphal 
growth, and elevated levels of the protective TNF-α and IFN-γ (Singh et al, 2009). 
SP-A and SP-D can also have a direct antimicrobial effect on the growth and viability 
of bacteria (Wu et al, 2003) including E. coli, K. pneumoniae, and Enterobacter 
aerogenes, and Histoplasma capsulatum (McCormack et al, 2003) by making 
bacterial membranes more permeable. SP-A can attenuate the growth of M. 












Figure 1.8. Multi-functional SP-A and SP-D.  The two hydrophilic pulmonary surfactant proteins 
bind a wide range of pathogens and act as high affinity opsonins for bacteria, viruses, and apoptotic 
cells. Their defensive mechanisms include agglutination or aggregation of pathogens, direct growth 
inhibitory effects, enhancement of phagocytosis, and modulation of cytokine/chemokine response by 







Figure 1.9 Homeostatic functions of SP-A and SP-D in human health and disease. In addition to 
their defense mechanisms in the lungs, SP-A and SP-D also have extra-pulmonary existence. Their 
immunomodulatory effects are more evident in pregnancy by virtue of their presence in the amniotic 
fluid as well as amnion, chorion and decidua (Nayak et al., 2012). Their interaction with glycoprotein 
allergens that eventually leads to modulation of type I and type III hypersensitivity reactions is another 
facet of the surfactant proteins SP-A and SP-D. 
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2.7 1.7. Role of SP-A and SP-D in allergy 
SP-A binds to pollen grains derived from Lombardy Poplar, Kentucky blue grass, 
cultivated rye and short ragweed, and links them with A549 alveolar type II cells 
(Malhotra et al, 1993). SP-A, SP-D and rhSP-D also bind house dust mite extract 
(Derp) and 3-week culture filtrate (3wcf) of A. fumigatus, inhibit specific IgE binding 
to allergens, and block allergen-induced histamine released from basophils isolated 
from allergic patients (Wang et al, 1998; Wang et al, 1996; Madan et al, 1997b) . SP-
D can bind starch granules of grass pollen allergens and enhance phagocytosis by 
alveolar macrophages (Erpenbeck et al, 2004). SP-A and SP-D also reduce the 
proliferation of PBMC isolated from allergic asthmatic children (Wang et al., 1998), 
and suppress IL-2 production by PBMC (Borron et al, 1998) and IL-8 by activated 
eosinophils (Cheng et al, 1998).  
SP-A, SP-D or rhSP-D treatment in a murine model of allergic bronchopulmonary 
aspergillosis (ABPA) induced by A. fumigatus 3wcf alleviates a range of allergic 
immune responses (Madan et al, 2001), as evident by lowered eosinophilia and IgG 
and IgE antibody levels. This therapeutic effect lasted up to 4 days in the SP-A 
treated ABPA mice, and up to 16 days in the SP-D or rhSP-D treated ABPA mice. 
The levels of IL-2, IL-4 and IL-5 were decreased, while that of IFN-γ was raised in 
supernatants of the cultured spleen cells, indicating a marked pathogenic Th2 to 
protective Th1 polarization of helper T-cell immune response. Similar protective 
effects of rhSP-D have been observed in a murine model of lung allergy induced by 
Derp (Derp mice) (Singh et al, 2003 ; Liu, Zhu and Li, 2005; Strong et al, 2003; 
Strong, Reid and Clark, 2002) .  
SP-A and SP-D appear to offer protection against allergenic challenge at various 
levels, such as allergen masking, inhibition of allergen-IgE interaction and histamine 
release, suppression of the activation of sensitized basophils, mast cells or 
eosinophils, B and T-cell proliferation, modulation of DCs and macrophages, and Th 








Figure 1.10.  SP-A and SP-D can link innate and adaptive immune systems.  Due to their ability 
to modulate cytokine and chemokine production by innate immune cells such as macrophages and 
dendritic cells, SP-A and SP-D can alter T helper polarization during infection and allergy. In addition, 
their anti-proliferative effects on T and B cells, coupled with induction of apoptosis in activated T cells 
can alter the long-term potentiation of adaptive immune response. Thus, SP-D specially is adapted to 
a general immunosurveillance as it can eliminate dying cells via anti-inflammatory route. The two 
receptors involved with the two collectins at SIRP-alpha that specifically interacts with CRD domain 
leading to an anti-inflammatory state. The collagen region, on the other hand, interacts with 
calreticulin-CD91 complex bringing about a pro-inflammatory response leading to clearance of 






Figure 1.11 Sensitisation and priming immune mechanisms in asthma. SP-D, via its CRD region, 
can bind allergens and inhibit their interaction with allergen-specific IgE, which in return, can suppress 
histamine release from sensitized basophils and mast cells. In addition, SP-D can cause T cell 
polarization from a pathogenic Th2 to a protective Th1 response, thus suppressing IL-4, IL-5 and IL-
13 levels and enhancing interferon- levels. This appears to have a beneficial effect in the murine 





Figure 1.12 Protective mechanisms offered by SP-A and SP-D against lung allergy and 
infection caused by Aspergillus fumigatus. SP-A and SP-D can have protective effects against A. 
fumigatus caused allergy (ABPA) and well as infection. In the immunocompromised hosts, they can 
reduce the fungal burden via anti-fungal clearance mechanisms that also include raising the levels of 
TNF- and IFN-.   In the immunocompetent hosts, A. fumigatus via its secreted allergens and 
antigens can induce classical type I and type III hypersensitivity reactions. Therapeutic treatment can 
have protective effects via bringing down IgE and IgG levels and Th2 cytokine response.  (Kishore et 
al, 2002) 
The two pathogens that were selected for study in this thesis were Influenza A Virus 
and Aspergillus fumigatus, both well-known respiratory pathogens characterised for 
their interactions with SP-D. Their life-cycle and pathogenic mechanisms are being 
described below. 
2.8 1.8. Host-pathogen interaction involving IAV 
Influenza A virus (IAV) is an orthomyxovirus which causes acute illness of upper and 
lower respiratory tract in humans. It occurs seasonally 0.25 to 0.5 million mortality 
worldwide and 5 million cases of severe morbidity per year. IAV infects a variety of 
avian and mammalian hosts, such as people, birds, pigs, horses, seals, whales, and 
other animals, although the natural hosts of these viruses are wild birds. Subtypes of 
IAV are H1N1 and H3N2, are currently in circulation seasonally amongst people. 
Two membrane-bound surface proteins, hemagglutinin (HA) and neuraminidase 
(NA) are expressed by IAV on its envelope, which also characterize the IAV 
nomenclature (Zheng and Tao, 2013). Glycans of HA may be vital for antigenic drift, 
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thus allowing the IAV to circulate in the human population. Overtime, evolutionary 
studies suggested that the number of glycosylation increased after the emergence of 
IAV in humans (Gallagher et al., 1992), suggesting that increasing the number of 
glycan’s may prevent the binding of neutralizing antibodies to antigenic epitopes 
(Tate et al., 2014).  
HA binds to molecules that have sialic acid receptors, thus allowing the virus to infect 
many cell types due to the sialic acid receptor found ubiquitously. NA is a second 
surface viral protein, which cleaves sialic acid, allowing the release of virus. 
However, not all sialic acid-containing molecules bind to IAV with the same 
efficiency, suggesting that the viral strains have diverse receptor specificity. HA 
strains of avian influenza virus favour binding to sialic acids linked by α2-3 linkage, 
whereas the human influenza viral strains have preferential binding to α2-6–linked 
sialic acids. The replication of human IAV occurs in the upper respiratory tract, which 
has abundance of α2-6-linked sialic acids in humans (Baum and Paulson, 1990).  
1.8.1 Structure and life cycle of influenza virus 
The IAV genome contains 8 segments of single-stranded (Palese et al., 1980) 
negative-sense RNA that is encapsulated as individual rod-shaped ribonucleoprotein 
complexes (RNPs), giving rise to enveloped icosahedral viruses (Palese et al., 
1980). The 8 IAV genes encode for 12 major viral proteins: HA, NA, matrix 1 (M1), 
matrix 2 (M2), nucleoprotein (NP), non-structural protein 1 (NSP1), non-structural 
protein 2 (NS2) or nuclear export protein (NEP), polymerase acidic protein (PA), 
polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2) and polymerase 
basic protein 1-F2 (PB1-F2). RNPs have a vital role in the viral RNA replication and 
transcription, intracellular transport of the viral RNA and gene packaging into 
progeny particles. A viral RNA, a viral polymerase and many copies of the viral 
nucleoprotein can be found in each RNP (Zheng and Tao, 2013). 
The IAV life cycle begins with entry into the host cell, entry of viral RNPs into the 
nucleus, RNA replication and transcription, viral RNPs directed from the nucleus, 
and budding. At the entry stage of the virus, the HA spikes on the viral lipid 
membrane, which bind to sialic acid of the host cell membrane, and the receptor-
mediated endocytosis occurs, allowing the virus to enter the endosome of the host 
cell. Low pH (5 to 6) of late endosome allows the cleavage of conformation of HA, 
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followed by the release of hydrophobic peptide that injects into host membrane, thus 
leads to the fusion of viral and endosome membranes, and opens up the M2 ion 
channel, acidifying the viral core (Fontana et al., 2012). The acid nature of the viral 
core releases the RNP from M1, thus allowing the RNP to enter the cytoplasm of the 
host cell (Figure 5.1). After being released into the host cell, the RNP enters the 
nucleus, where viral transcription and replication occurs  (Shi et al., 2014). The 
proteins of the RNP (NP, PA, PB1, and PB2) have nuclear localization signals, which 
can bind to the cellular nuclear import machinery and enter the nucleus. The 
negative sense strands of RNA need to be converted into positive sense RNA for 
transcription to occur, by serving as a template for the viral RNA production. Viral 
RNA dependent RNA polymerase (RdRp) triggers the synthesis of viral RNA. RdRp 
is formed of three viral proteins: PA, PB1, and PB2 (has endonuclease activity), 
which binds to the 5’ methylated caps of the cellular mRNA cleaved 10 to 15 
nucleotides 3’ to the cap structure, thus viral transcription takes place (Nayak, Hui 
and Barman, 2004). 
Viral segment 7 encodes M1 and M2, and segment 8 encodes NS1 and NEP. M2 
and NEP are spliced products and are in lower amount than NS1 and M1 (Fujii et al., 
2003). Influenza hinders the splicing machinery of the host cell for the process of 
host cell mRNAs, and so uses the host cell splicing machinery to produce viral 
proteins  (Palese et al., 1980). Influenza is able to inhibit the splicing of cellular 
mRNAs, by the binding of NS1 to small nuclear RNAs (snRNAs), and so re-localising 
to the nucleus of infected cells (Figure 1.13). Once the viral RNPs leave the nucleus, 
the enveloped influenza virus uses the host cells plasma membrane forming viral 
particles to leave and infect other cells, budding of viral particles occurs on the apical 
side of polarized cells. NA removes the sialic acid residues from glycoproteins and 






Figure 3.13: Structure and life cycle of influenza A virus: (a) Influenza A virus is a single stranded, 
encapsulated negative sense RNA, enveloped icosahedral virus. It contains 8 gene segments, which 
may encode for 16 proteins as follows: nuclear export protein (NS2), host antiviral response 
antagonist (NS1), matrix protein (M1), ion channel protein (M2), and the M2-related protein M42 
(which can functionally replace M2), hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), 
components of the RNA-dependent RNA polymerase complex (PB1, PB2 and PA), two recently 
recognised proteins N40 (unknown function) and PA-X, represses the cellular gene expression. 
Additional two forms of PA (which have amino-terminal truncations) have been identified, which may 
have vital functions in the replication cycle. Furthermore, PB1-F2 is a pro-apoptotic viral protein, 
encoded by second ORF in the PB1 segment. (b) Infection begins when the virus binds to the sialic 
acid of the host cell-surface receptors, and enters by endocytosis. The segmented viral genome is 
released into the cytoplasm, translocated to the nucleus causing transcription and replication. Within 
the nucleus the viral proteins are composed into viral ribonucleoproteins (RNPs). M1 and NS2 
mediate the export of RNPs. The virus particles are formed at cell membrane and the newly formed 
viruses bud and infect other cells (Taken from  (Shi et al., 2014) . 
1.8.2. Pathogenic mechanisms 
IAV can be transmitted by inhalation of infectious particles, or by airborne droplet 
nuclei, and by direct contact. Human IAV infections that caused pandemic are H1N1 
(1918, 2009), H2N2 (1957) and H3N2 (1968) (Taubenberger and Morens, 2010). 
The risks attributed to seasonal or pandemic influenza, causing severe complication 
and death include age (very young or old), underlying chronic respiratory and 
cardiovascular conditions, diabetes mellitus, pregnancy and immunosuppression. 
Although drugs are available for treatment, drug-resistant mutations can emerge. 
Signs and symptoms include dry cough, chills, sweats, myalgia, shortness of breath, 
and neurological symptoms (Weycker et al., 2005).  
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1.8.3. Innate immune involvement with IAV 
IAV recognition by PAMPs via PRRs leads to antiviral signalling cascade, causing 
regulation of interferons, cytokines and chemokines. TLRs, RIG-1 and NOD- like 
receptor family pyrin domain containing 3 (NLRP3) are the three main PRRs 
involved in the recognition of IAV. For instance, of TLR 2, 3, 4, and 7, TLR7 
recognises single stranded viral RNA (ssRNA) while TLR3 recognises viral RNA in 
endosomes (van de Sandt, Kreijtz and Rimmelzwaan, 2012). Human respiratory 
epithelial cells express TLR3, which stimulates the activation of pro-inflammatory 
cytokines following IAV infection. Thus, TLR3 knock out mice become resistant to 
lethal IAV challenge as compared to wild type, concomitant with reduced chemokine 
expression, leukocytes and CD8+ T cells. It is apparent that TLR3 induced immune 
response against IAV challenge is not protective. Although TLR3 expression signals 
the inhibiting effect on viral replication, it also induces host cell damage (Iwasaki and 
Pillai, 2014) TLR7 on plasmacytoid DCs recognises viral ssRNA when released into 
the endosome, activating the NF-κB and IRF7, and inducing pro-inflammatory 
cytokines and/or type I IFNs (Iwasaki and Pillai, 2014). TLR2 and TLR4 recognise 
HA and NA while RIG-1 receptor recognises viral RNAs.  
Neutrophils, macrophages and maturation of DCs are activated by IAV infection. 
During the initial phase of infection monocytes and macrophages are recruited via 
their CCR2 receptor. Epithelial cells produce CCL2 during IAV infection. Viral spread 
is reduced as the apoptosing infected cells are phagocytosed by alveolar 
macrophages. Infected cells can also be lysed by natural killer (NK) cells in a MHC 
class I dependent manner, may rely on an interferon gamma dependent 
autocrine/paracrine loop. Infected cells can be directly lysed due to the binding of 
sialylated NKp44 and NKp46 binding to HA viral protein (Bar-On et al., 2014) . On 
the other hand, the indirect manner of lysing infected cells is when the NK cells with 
CD16 receptor bind to the Fc portion of antibodies that are bound to IAV infected 
cells, causing lysis of infected cells (Klimpel, 1996).  
1.8.4. Adaptive immune response against IAV 
Adaptive immunity against IAV involves virus-specific humoral as well as cellular 
immune response (van de Sandt, Kreijtz and Rimmelzwaan, 2012). Antibodies 
against HA can inhibit the attachment of the virus to host cells, and thus blocking 
receptor-mediated endocytosis as well as neutralisation of IAV. Since antibodies 
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against HA are strain-specific, depending on the epitopes involved, they cannot 
neutralise antigenic drift variants. Neutralizing antibodies offer a long-lasting 
protection against strains that are similar to the infected strain. In 1950s individuals 
exposed to H1N1 virus had developed antibodies that cross-reacted with pandemic 
strain and may develop immunity against infections and disease of present 
pandemics. High frequency of cross-reacting antibodies against 2009 pandemic 
H1N1 virus has been reported among the elderly in Finland in 2010. Antibodies 
against NA are involved in the last phase of viral replication cycle; however they are 
non-neutralizing antibodies. These antibodies also inhibit the enzymatic activity of 
NA, thus reducing viral spread (van de Sandt et al., 2012). DCs infected with IAV 
participate in anti-viral response via MHC class I mediated peptide presentation to 
CD8+ CTLs. Alternatively, viral peptides can also be presented by MHC class II 
molecules to CD4+ T cells (van de Sandt et al., 2012). Over the period it has become 
apparent that both CD4+ and CD8+ T cells are important for heterosubtypic immunity 
and hence viral clearance in vivo. In spite of a lack of protective antibody response B 
cell deficient mice can still clear IAV infection suggesting a more profound role of T 
cells in anti IAV defence (Altenburg et al., 2015).   
1.9. Aspergillus fumigatus, a fungal pathogen  
Several species of Aspergilli, such as A. flavus, A. fumigatus, A. niger and A. terreus 
can act as human pathogens (Thiagarajan et al, 2005). A. fumigatus spores, 2-3 µm 
in diameter, are universal in distribution. Given that 0.1-22% of total spores exist in 
the air, they can easily deposit in the lungs up to the alveolar level (Latge, 1999). 
However, A. fumigatus shows higher pathogenic potential due to production of large 
numbers of small conidia, presence of number of conidial adhesins, resistance to 
oxidative stress and thermotolerance (Latge, 1999). In addition, it produces gliotoxin 
that affects the circulating neutrophils, inhibits phagocytosis and enhances 
dissemination of the organism (Scharf et al, 2012). Another virulence factor 
produced by A. fumigatus is pigment melanin that inactivates the C3 component of 
the complement system (Knutsen and Slavin, 2012).  
A. fumigatus, a major opportunistic fungal pathogen, causes a spectrum of 
respiratory diseases, depending on the immune status of the host. In the healthy 
host, the inhaled conidia of Aspergillus seldom cause any adverse effects 6. The 
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innate and adaptive immune responses in a healthy individual result in the 
mucociliary clearance and phagocytosis of spores (Wannar et al, 1996). In the 
hypersensitive individuals, the fungal sensitization mostly results in allergic 
manifestations with allergic bronchopulmonary aspergillosis (ABPA). About 2% of 
patients with asthma and 1-15% of patients with cystic fibrosis develop ABPA. In the 
immunocompromised host, the fungus invades various organs leading to systemic 
form of infection, termed as invasive pulmonary aspergillosis (IPA). The hyphal 
invasion causes destruction of pulmonary tissue, followed by dissemination of fungus 
to other organs in approximately 20% cases (Wannar et al, 1996). The number of 
IPA cases has risen with the increasing incidence of AIDS, organ transplantations 
and aplastic anemia, etc. The immunity of host is compromised due to pathogens 
such as HIV or prolonged treatment with corticosteroids or aggressive antineoplastic 
chemotherapeutic regimens. IPA results in > 80% mortality, and up to 95% among 
patients of bone marrow transplantation (Patterson, 2002). To understand the role of 
collectins, murine models of ABPA and IPA in wild type and collectin gene deficient 
mice have been studied.  
Host defense against Aspergillus infections is mediated by phagocytic cells including 
macrophages and neutrophils. Macrophages can bind and phagocytose A. fumigatus 
conidia, and kill conidia as well as hyphae. Innate immune molecules, such as 
collectins, toll-like receptors and pentraxin-3 are known to be involved in lung 
resistance to A. fumigatus infection (Schaffner et al, 1982). SP-A and SP-D bind and 
agglutinate A. fumigatus conidia in vitro in a sugar and calcium dependent manner 
and thus, enhance killing of conidia by circulating neutrophils and alveolar 
macrophages via phagocytosis and superoxidative burst (Madan et al, 1997a). In 
vitro interactions of SP-A and SP-D with A. fumigatus allergens/antigens suggest 
their hierarchical role at various levels that involves allergen scavenging, inhibition of 
allergen-IgE cross-linking and histamine release, suppression of the activation of 
sensitized basophils or mast cells 31-35. SP-A and SP-D can also modulate host 
immune response by suppression of B- and T-cell proliferation, modulation of 





1.9.1. Murine models of allergic aspergillosis  
Allergic aspergillosis comprises a spectrum of allergic diseases induced by 
Aspergillus species in non-immunocompromised patients and are defined as 
hypersensitivity disorders. ABPA is the most severe and fatal form of allergic 
aspergillosis and occurs predominantly in patients predisposed with lung diseases 
such as cystic fibrosis or bronchial asthma (Burton and Oettgen, 2012). In these lung 
diseases, the A. fumigatus spores are not effectively cleared off. They germinate and 
grow to hyphae in the mucus plugs. The host suffers from an allergic disorder 
characterized by Type I and Type III hypersensitivity response to the secreted A. 
fumigatus allergens, antigens toxins and hyphae. The common features of Type I 
hypersensitivity in ABPA are upregulation of TH2 cytokine pathway that includes IL-
4, IL-5, IL-6, IL-10 and IL-13 cytokines (Madan et al, 2001). Presence of IgE 
antibodies specific to A. fumigatus sensitizes and causes mast cell degranulation 
resulting in bronchoconstriction and increased capillary permeability. Further, 
immune complexes are formed because of type III reaction and the inflammatory 
cells get deposited in the mucous membranes leading to necrosis and eosinophilic 
infiltration of the airways. Briefly, clinical ABPA is characterized by Rosenberg et 
al.41 in terms of episodic bronchial hyper-reactivity, reversible airway obstruction, 
positive immediate skin reactivity, peripheral and pulmonary eosinophilia, central 
bronchiectasis and history of expectorating brown plugs or flecks, etc.  
Experimental murine models of ABPA have been generated in various strains of 
mice. The development of ABPA has been linked to a number of genetic risks, which 
include polymorphisms in the genes of HLA-DR and HLA-DQ, surfactant protein A2 
(SP-A2), IL-4 receptor alpha chain (IL-4RA), and IL-10-1082GA promoter (Brourad, 
2005). Cystic fibrosis transmembrane conductance regulator gene (CFTR) mutations 
and TLR polymorphisms are also linked to ABPA. The effect of genetic variation is 
also observable in murine fungal exposure studies. Of the three congenic mouse 
strains (BALB/c, CBA/J, C57BL/6), BALB/c mice exhibit the strongest inflammatory 
response. The BALB/c species is more sensitive to hypersensitivity disorders, while 
C57BL/6 mice are comparatively more resistant (Atochina et al, 2003). An enhanced 
lung SP-D production has been predicted to attenuate airway hyper-responsiveness 
to allergic airway sensitization in C57BL/6 mice51, suggesting an important role of 
SP-D in regulating pathogenesis in ABPA.  
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Important features of ABPA model can be developed in mice genetically predisposed 
to atopy (e.g. BALB/c) by the continual exposure and sensitization of the airways to 
A. fumigatus allergens. Type I and Type III immune responses are present in these 
models. In case of natural disease, this happens by the growth of A. fumigatus 
spores into the hyphal structures in the lungs. Spores present in central and up to 
distal parts of the lungs release allergens continuosly which inturn lead to clinical 
symptoms of ABPA. A variety of experimental animal models of ABPA have been 
studied depending on the pathogen form, inoculum size (conidia/hyphae/allergens) 
and the frequency and route of exposure in addition to variations on the basis of 
strain of animals (Kishore et al, 2002).  
The BALB/c murine models of ABPA have demonstrated nine-fold increase in SP-D 
levels on A. fumigatus-induced allergic airway inflammation suggestive of its role in 
pathophysiology. Treatment with SP-A and SP-D drastically decreases the serum A. 
fumigatus IgG and A. fumigatus IgE levels in murine models of ABPA (Madan et al, 
2001). The decrease in specific IgG and IgE levels persist till 16 days in the SP-D 
treated ABPA mice, but only 4 days in SP-A treated mice. SP-D treated murine 
ABPA models show significant decline in peripheral blood eosinophilia and lung 
eosinophil peroxidase activity, hallmarks of Type I hypersensitivity. The chronic 
inflammatory infiltrates disappear and the ABPA mice model showed higher levels of 
A. fumigatus specific IgE and IgG levels as well as peripheral blood eosinophilia. 
Increased ratios of IL-2, IL-4 and IL-5 and levels, while a decrease in IFN- were 
observed in splenic supernatants of the untreated ABPA mice compared to their 
respective controls, indicating a marked shift from Th2 to Th1 response. Thus, 
collectins have a major role in modulation of allergic reactions in ABPA.  
Murine models of ABPA in SP-A gene deficient (AKO), SP-D gene deficient (DKO), 
and WT mice in C57BL/6 background were used for such studies (Madan et al, 
2005). The studies showed that both AKO and DKO mice exhibit intrinsic 
hypereosinophilia and several fold increase in levels of IL-5 and IL-13, and decrease 
in IFN- to IL-4 ratio in the lungs. DKO mice develop chronic inflammation, foamy 
alveolar macrophages secreting 10-fold higher levels of hydrogen peroxide, 
increased activity of metalloproteinases, emphysema, and fibrosis in the lungs. 
Administration of SP-A or SP-D to the respective knockout mice decreases 
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peripheral eosinophil count, EPO activity, IL-13, IL-5, and increases TNF- and IFN-
 levels. The Th2 bias in AKO or DKO mice was reversible on treatment with SP-A or 
SP-D, respectively.  
The A. fumigatus allergen sensitization of AKO and DKO mice further increases the 
Th2 response, as opposed to the predominantly Th1 profile of the WT C57BL/6 
mice. DKO mice are more susceptible than WT mice to pulmonary hypersensitivity 
induced by A. fumigatus allergens. DKO mice also develop 2-fold elevated peripheral 
eosinophil count with increased eosinophil infiltration around perivascular areas in 
the lung sections on allergen treatment. A more pronounced Th2 bias of DKO mice 
is also evident by decrease in IFN- levels and increase in IL-13, IL-5, and IL-2. 
However, IL-4, IL-10, IL-12, and TNF- levels in both AKO and DKO mice do not 
show significant changes compared to WT mice challenged with allergens (Madan et 
al, 2005). The intranasal treatment with SP-D is effective in rescuing the A. 
fumigatus sensitized DKO mice. A. fumigatus IgE levels, peripheral eosinophilic 
count, pulmonary eosinophilia and EPO activity also decrease. SP-D treatment to 
DKO mice also reduces IL-13 and IL-5 cytokines and increases IFN- to IL-4 ratio. 
SP-A-treated A. fumigatus-sensitized AKO mice develop several fold elevated levels 
of IL-13 and IL-5, resulting in increased pulmonary eosinophilia and lung tissue 
damage. Hence, SP-A and SP-D may be helpful in treating ABPA, as evident from 
studies of murine models.  
1.9.2. Invasive Pulmonary Aspergillosis 
Deficiency of innate and adaptive immune response, induced by infectious agents 
such as HIV or the organ transplant immunosuppressive regimens, makes the host 
susceptible to germination and invasion of inhaled fungal conidia. In the patients of 
IPA, there is low or almost no humoral immunity while the adaptive immune 
response is of Th2 type. Recovery of these patients on empirical treatment with 
antifungal drugs is accompanied by revival of innate immunity and a protective Th1 
type of response.  
To mimic the human IPA, murine model of IPA can be generated by administration of 
immunosuppressive agents, such as cyclophosphamide, hydrocortisone acetate and 
FK506, etc., followed by fatal spore challenge(s) (Herbst et al, 2013). The survival 
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rate and enumeration of pulmonary colony forming unit (CFU) serve as the markers 
of therapeutic evaluation.  
Intranasal administration of SP-D or a recombinant fragment of SP-D composed of 
trimeric neck and CRD regions (rhSP-D) have protective effect in a murine model of 
IPA, where mice are immunosuppressed with hydrocortisone and challenged 
intranasally with A. fumigatus conidia (Madan et al, 2001b). Untreated IPA mice have 
100% mortality in 7 days, whereas SP-D or rhSP-D treatment rescued 80% of the 
IPA mice. Interestingly, SP-A does not have significant effect on survival, while SP-D 
plays an important role in the ability of host to resist A. fumigatus challenge and 
subsequent infection. The rhSP-D treatment lowers IL-4, IL-5 and increases TNF-
and IFN- levels in the lung cell suspension, as compared to untreated IPA mice.  
The immune status of AKO as well as DKO mice alters distinctly following steroid 
treatment prior to A. fumigatus conidia challenge (Madan et al, 2010). DKO mice 
have increased susceptibility to the IPA pathogenesis than the WT mice while AKO 
mice are more resistant than WT mice. Intranasal treatment with SP-D or rhSP-D 
was effective in ameliorating the pathology in the case of DKO mice, whereas the 
SP-A treated A. fumigatus challenged AKO mice have increased mortality. The 
survival data also reflected on the CFU counts and hyphal burden in the lung, 
consistent with the lung cytokine profiles. Thus under immuno-suppressed or 
immunocompromised conditions, the SP-A or SP-D deficiency may have profound 
but contrasting effects on host immune response.  
The main aims and objectives of the thesis are as follows: 
1. To optimise large scale expression and purification of LPS-free rhSP-D, 
composed of trimeric neck and CRD regions; 
2. To test their interaction with IAV and examine the nature and ligands involved 
in this interaction; to examine the effect on infectivity of IAV bt rhSP-D; 
3. To assess the in vitro effects of rhSP-D on spleen cells derived from murine 
ABPA model; to examine direct effect of rhSP-D on the conidia of Aspergillus 
fumigatus in the absence of phagocytic cells; 
4. To measure the effects of full-length SP-A and SP-D on the maturation, 




Thus, this thesis examines interaction of a recombinant fragment of human SP-D 
containing neck and CRD regions (rhSP-D) with IAV and Aspergillus fumigatus, 
in addition to characterizing a dichotomy of the effects of SP-A and SP-D on 
dendritic cells in an attempt to explain how SP-A and SP-D modulate DC 
functions differentially. Chapter 3 examines interaction of rhSP-D with IAV 
pandemic strain showing that it can be a restrictive factor against the virus, in 
addition to modulating immune response by a macrophage cell line. Chapter 4 
looks at how rhSP-D can modulate anti- A. fumigatus responses directly and 
indirectly in the context of pathogen as well as allergen. A comparison has been 
made between two recombinant fragments of SP-D that have been expressed 
with and without 8 Gly-X-Y repeats for their fungistatic properties. Finally, 
Chapter 5 examines effect of SP-A and SP-D on cultured DC maturation, and 

















2. Chapter 2 






















2.1. Purification of native of full length SP-A 
One litre of pooled amniotic fluid was thawed by incubating at 37°C for 6 hours 
(occasional mixing), amniotic fluid was passed through 3mm Whatman filter paper. 
Use of a cell strainer further removed fat and other large aggregates. The sample 
was centrifuged at 14000 g for 30 min at 4°C. 20 ml of 8 M urea in the affinity buffer 
(50 mM Tris- HCl, pH 7.4, 100 mM NaCl, 5 mM CaCl2, and 0.02% NaN3) was added 
to the pellet for further SP-A extraction. After stirring for 1 hour at 4°C, the 
suspension was centrifuged at 14,000 x g for 15 min at 4°C. The supernatant was 
then dialysed against 1 Liter of affinity buffer without urea overnight at 4°C. The 
dialysate, after another round of high-speed centrifugation, was subjected to affinity 
chromatography procedure. Maltose-Sepharose was washed with 5 ml bed volumes 
of distilled water and then equilibration with 4 volumes of affinity buffer. The 
equilibrated maltose-Sepharose was added to the supernatant containing SP-A and 
left to stir for 30 min at RT, and then packed into a Bio-Rad column. After few wash 
with the affinity buffer, SP-A was eluted with elution buffer (50 mM Tris- HCl, pH 7.4, 
100 mM NaCl, 5 mM EDTA, and 0.02% NaN3). 1 ml fractions were collected and 
analysed for protein concentration by Nanodrop and purity by 12% SDS-PAGE. 
2.2. Purification of native of full length SP-D 
Amniotic fluid was processed first as described above. The amniotic fluid was made 
5 mM with CaCl2 and the supernatant from the first round of centrifugation was 
purified using maltose-agarose (Sigma) and eluted with MnCl2 (Strong et al, 1998). 
100 µl of each fraction was used for TCA precipitation and this was separated on a 
15 % SDS-PAGE to visualize protein concentration and purity.  
2.3. Expression and purification of trimeric SP-D 
2.3.1. Competent cells preparation  
A single colony of E. coli BL21 (λ DE3) pLysS (Invitrogen) in 10 ml of Luria broth 
(LB) media with 10µl of chloramphenicol (stock: 50 mg/ml dissolved in ethanol) 
overnight at 37°C shaker. Next day, 500 µl was removed from culture and inoculated 
into 25 ml LB containing 25µl chloramphenicol and put on a shaker.  A600 of the 
culture was measured every hour until it reached 0.3 values. The culture was 
centrifuged at 2,000 x g for 5 minutes.  After centrifugation, the supernatant was 
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discarded, and 12.5 ml of sterile 0.1 M CaCl2 was added to the cell pellet. The cells 
were suspended and placed in the temporary state of competent at ice for an hour. 
After an hour, the cells were centrifuged for 5 minutes at 2000 x g.  The supernatant 
was discarded, and the pellet was re-suspended in 2 ml of 0.1 M CaCl2 and was 
stored in ice. 
2.3.2. Transformation of cells  
200 µl of cells from the competent cells that prepared earlier were removed and were 
placed in a 10 ml falcon tube containing 1-2 µl of (pUK- D1) construct. The mixture 
was placed on ice for an hour. The mixture was exposed to heat shock at 42°C for 
90 seconds. Following heat shock, the cells were placed on ice for a further 5 
minutes, and then re-suspended in 800 µl of LB. The mixture was placed inside a 
37°C incubator for approximately 45 minutes. After incubation, the cells were 
streaked on an LB agar plate containing Ampicillin/ Chloramphenicol and were left 
inside a 37°C incubator overnight in order to grow.  
2.3.3. Protein Expression 
A single colony of transformed (pUK-D1 and D2) cells was grown in 25 ml LB along 
with 100 µg/ml Ampicillin + 50 µg/ ml chloramphenicol overnight in a shaker at 37° C. 
On the following morning, the overnight primary culture of 25 ml bacterial culture was 
inoculated into 1 L LB along with 100 µg/ml Ampicillin + 50 µg/ ml chloramphenicol 
and was grown inside a 37°C shaker, until the absorbance A600 reached 0.6 – 0.8 . 
After the cells reach log phase (A600 at 0.6- 0.8) were induced with 0.4 mM IPTG for 
3 h and harvested by centrifugation at 9,000 x g for 15 minutes. Following 
centrifugation, the supernatant was discarded and the pellet was stored at - 20°C for 
further processing. 
2.3.4. Cell Lysis   
The cell pellet that obtained after IPTG induction was resuspended in ice cold lysis 
buffer containing (50 mM Tris-HCL, 200 mM NaCl, 5 mM EDTA, 0.1 % v/v Triton X-
100, 0.1 mM PMSF, pH 7.5, 50 µg/ ml lysozyme) and was vortex for 1 hour in cold 
room at 4°C and then sonicate the sample (ten cycles at 30 seconds each). 
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2.3.5. Dialysis   
The sonicate was harvested by centrifugation at 9,000 x g for 15 minutes and was 
solubilized the recovered rh SP-D in the inclusion bodies in 100 ml buffer I (50 mM 
Tris- HCl pH 7.5, 100 mM NaCl) containing 10 mM 2- Mercaptoethanol and 8 M 
Urea. Carry out a stepwise dialysis of the resolubilzed material against buffer I 
containing 4M urea, 2 M urea, 1 M urea and no urea, each for 2 hours. The dialysate 
was clarified by centrifugation at 9,000 x g for 15 minutes, and then dialyzed with 
calcium buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl2, 0.05 % sodium azide) for 3 
hours to completely remove urea from the dialysate. 
2.3.6. Protein Purification by Affinity chromarography 
The rhSP-D is purified by affinity chromatography using maltose- sepharose column. 
The maltose- sepharose column was rinsed with distilled water prior to use.  After 
through rinsing of the column with dH2O, 50 ml of affinity column buffer (50 mM Tris-
HCl pH 7.5, 100 mM NaCl, 5 mM CaCl2, 0.05 % sodium azide) was passed through 
the column. After rinsing the column, the protein was passed through the column 
once, and then the column was washed with affinity column buffer. The bound 
protein was eluted by using elution buffer containing 5 mM EDTA (25 ml) (50 mM 
Tris- HCl pH 7.5, 100 mM NaCl, 5 mM EDTA. 0.05% sodium azide. The affinity-
eluted protein ran as a trimer on a Superose-12 gel filtration column. 
2.3.7. Endotoxin Removal from Recombinant SP-D   
5 ml of Polymyxin B agarose gel (sigma) was packed in a 20 ml column. The column 
was washed with 50 ml of 1% sodium deoxycholate and then further rinsed with 50 
ml of autoclaved distilled water to completely removed 1 % sodium deoxycholate. 
After rinsing the column, the protein was loaded on to the column, and left to be 
incubated at room temperature for half an hour for the protein to bind completely. 
After the incubation period, the protein was eluted and collected in 0.1 ml fractions. 
The LPS-free rhSP-D protein was then checked for purity by running it on 15 %SDS 
gel to ensure the removal of LPS. The endotoxin level was examined by QCL-1000 
Limulus amoebocyte lysate system (Bio Whittaker, Walkersville, MD, USA) and was 
found to be µg-1 of rhSP-D. The protein was furthered quantified by measuring the 




2.3.8. Preparation of D-Maltose-Sepharose 4B Column 
Sepharose was first activated with the bifuctional reagent divinyl sulfone (DVS, 
Sigma), and then coupled under basic conditions to the hydroxyl of D- mannose. 
Reductive amination, epoxy and DVS activation provide three excellent alternatives 
for the obtaining an optimal affinity support. Activated sepharose 4B (100ml settled 
gel with DVS), DVS is a bifunctional cross- linking reagent, used to activate agarose 
and other hydroxyl matrices.  DVS introduces reactive vinyl groups into the matrix 
that will couple to amines, alcohols, sulfhydryls, and phenols. DVS activated gels 
were more reactive than epoxy-activated gels and therefore coupling proceeds 
rapidly and completely.  
2.4.    Activation 
100 ml of sepharose 4B gel was washed with 1 litter water and then suspended in 
0.5 M sodium carbonate. While stirring, 10 ml of DVS was slowly added drop wise. 
The gel suspension was stirred for 1 hour at room temperature followed by extensive 
washing with water. 
2.5.    Immobilization  
D-maltose solution (20 % D-maltose in 0.5 M sodium carbonate) was added to the 
gel and stirred at room temperature for 24 hours. After filtration and washing with 2 
Litre of water and 0.5 M sodium bicarbonate containing 5ml beta-mercaptaethanol at 
room temperature, the gel was mixed for 2 hours to block the excess vinyl groups. 
Finally, the gel was washed with 2 L each of water. D-maltose-sepharose 4B can be 
stored in 0.02% sodium azide at 4°C. 
2.6.    Bis (Sulfosuccinimidyl) substrate (BS3) Cross-Linking 
25 mM solution of BS3 was prepared by dissolving 2 mg BS3 in 140 µl of DMSO. 
BS3 cross-linker solution was added to the protein sample at the concentration of 0.5 
and 5 mM. rhSP-D was incubated with different concentrations (1 mM, 0.1 mM, and 
0.01 mM BS3). After 45 minutes incubation, BS3 was quenched with 60 mM Tris-
HCl, pH 7.5 for 15 minutes at room temperature. The SDS-PAGE was run for the 
detection of cross-linking.  
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2.7.     TCA Assay   
An equal volume of 20 % TCA (trichloroacetic acid) was used to precipitate the 
protein.  
2.8.        Bicinchoninic Acid Protein Assay   
BCA assay was used to estimate the protein concentration as per the kit instructions, 
using BSA (2 mg/ml) as a control protein (Thermo Scientific).  
2.9.        SDS- PAGE: 12% and 15%  
For a standard size gel, 10 ml of resolving gel and 5 ml of stacking gel was used to 
run a denaturing polyacryamide gel following standard method. Commercial stain 
and destain solutions based on Coomassie blue R250 were used for the gels.   
2.10. IAV amplification and purification (H3N2, H1N1) 
Madin-Darby Canine Kidney (MDCK) cells were cultured in complete DMEM (Fisher 
Scientific) consisting of 10% v/v FBS, 2mM L-glutamine, 100U/ml penicillin, 100µg/ml 
streptomycin and 1mM sodium pyruvate in four 150 cm2 flasks (Fisher Scientific), 
and left to grow in 5% CO2 at 37ºC incubator, until about 80% confluence was 
reached. Cells were then washed with PBS twice, and infected with 3.3 x 104 pfu/ml 
virus titre with 10ml of pure DMEM to the flasks. The flasks were left for 1h to allow 
the virus to adsorb in 5% CO2 at 37ºC incubator, and every 15 min tilted to avoid 
drying up of the cells. The cells were then washed with 20ml PBS to remove any 
unabsorbed virus, and 25ml of infection medium (DMEM, 1% penicillin/streptomycin, 
1μg/ml TPCK-Trypsin, 0.3% BSA) was added to flasks, left at 5% CO2 at 37 º C 
incubators for 3 days. 
2.11. Purification of IAV by ultra-centrifugation and sucrose  
cushion 
After 3 days of infection, infected cells detached, and added to 50ml falcon tubes 
(Fisher Scientific) and centrifuged at 3000 rpm at 4ºC for 15 min. The supernatant 
was transferred to ultra-clear centrifuge tube (Beckman Coulter), balanced with PBS, 
and centrifuged at 10,000 rpm for 30 min at 4ºC. 8ml of cold 30% w/v sucrose was 
added to new ultra-clear centrifuge tubes and 26ml of supernatant was transferred 
carefully into the tubes containing 8ml sucrose, and centrifuged at 28000 rpm at 4ºC 
for 2 h. Then the supernatant in the upper phase was carefully removed and sucrose 
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phase was removed. The pellets from all tubes were re-suspended in 100μl of PBS, 
and collected in a screw-capped tube. The virus suspension was briefly spun, then 
aliquoted in new screw-capped tubes and stored at -80ºC. 
2.12. Haemagglutination assay 
Haemagglutination assay carried out to determine the titration of IAV, which allows 
the virus to attach to the surface of red blood and may cause them to agglutinate and 
prevent from settling. Guinea pig red blood cells (RBC) (TCS biosciences) were 
washed twice with 1 X PBS at 800 g for 5 min. RBCs were made to 10% v/v solution 
in 1 X PBS, and the final working solution used was 0.75% RBCs in PBS. 50μl of 1 X 
PBS was added to each well of maxisorp 96 well plate. To the first wells of the plate, 
50μl of IAV were added (total volume 100μl) and 50μl was serially diluted until the 
last well of the plate, discarding the last 50μl. The plate was mixed by tapping and 
left at room temperature for up to 2 h and photographed. PBS was used as control. 
Settled cells appeared as halo indicating negative results. Positive results gave a 
uniform red colour of cells that do not settle. The titre used for the HAI assay was the 
dilution that the virus did not allow the cells to settle down. 
2.13. Haemagglutination inhibition assay (HAI) 
In maxisorp 96 well plate, 25μl of 1 X PBS was added to each well. In the first 
column starting concentration (total volume 50μl) of 5 and 10 μg of rhSP-D, were 
serially diluted (25μl). Controls used were no protein and PBS only. All strains were 
diluted accordingly to the haemagglutination assay in PBS and 25μl of respective 
IAV were added to wells except for PBS control wells. Plate was gently mixed by 
tapping and left at 37°C for 1 h. 50μl of 0.75% guinea pig RBC working solution was 
added to each well, plates were gently tapped to mix, and left at room temperature 
for 1 h to develop. Inhibition of haemagglutination will appeared as halo or circle of 
settled cells in the centre of round-bottomed plates. Absence of inhibition was 
evident from a uniform reddish colour across the well (haemagglutination).  
2.14. Binding of H3N2 influenza A virus to rhSP-D 
Maxisorp 96 well plates were coated with 5 or 10μg of rhSP-D in carbonate 
bicarbonate buffer and left overnight at 4ºC. Microtitre wells were then blocked with 
2% w/v BSA for 2 h at 37ºC, and washed 3 times with PBS. Different amounts of 
H3N2 virus were added (10, 5, 2.5 and 1.25μl) and left at 37ºC for 2 h. The binding 
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was probed with anti-Udorn antibody (goat anti-serum against A/Udorn/72 (H3N2) 
influenza virus was a kind gift from Dr Jeremy Rossman (University of Kent, UK) 
(1:5000; 100μl/well) in PBS for 1 h at 37ºC. Wells were washed again with PBS and 
incubated with rabbit anti mouse IgG HRP (1:5000) in PBS (100μl/well) for 1 h at 
37ºC. Colour was developed using TMB and the reaction was stopped using 2N 
H2S04. Absorbance was read at 450 nm.  
2.15. Western blot of rhSP-D bind to H3N2 
5μl of H3N2 lysate was loaded onto SDS PAGE, and run at 120 volts until the dye 
front reached the end of the gel, which was then transferred onto a nitrocellulose 
membrane by electrophoresis in 1 X transfer buffer (25mM Tris, 192mM Glycine, 
20% v/v methanol, pH ~8.3) at 320 mA for 2 h. The nitrocellulose membrane was 
incubated in blocking solution (5% semi-skimmed milk powder (Tesco, UK) in PBS, 
pH 7.4) overnight at 4°C. The membrane was then washed in PBST three times, 10 
minutes each. The blots were incubated with either anti-H3N2 polyclonal antibodies 
(1:500) in PBS or with purified rhSP-D (10μg). PA-HRP (1:1000) in PBS was 
incubated correspondingly to the blot hybridised with anti-H3N2 antibody. Anti-
human SP-D (polyclonal) (1:5000) in PBS was added to blot hybridised with 
properdin. The membranes were incubated for 1 h at 37ºC, and washed with PBST 
three times for 10 min each. The secondary probe used was rabbit protein A HRP for 
properdin membrane. The membranes were then washed in PBST three times for 10 
min each, and developed colour using DAB. 
2.16. rhSP-D binding to H1 and N1 proteins 
Microtitre wells were coated with different concentrations of H1 or N1 (12.5, 6.25, 
3.125, 1.56, 0.78 and 0.39μg) in carbonate bicarbonate buffer. Wells were then 
blocked with 2% w/v BSA in PBS, and added 10μg/ml of rhSP-D to 100μl to each 
well. Polyclonal anti-human SP-D (1:5000) in PBS was added to each well, and then 
probed with PA-HRP (1:5000). Colour was developed using TMB and reaction was 
stopped using 2N H2SO4. Absorbance was read at 450 nm.  
2.17. Infection assay using U937 monocytic cell line 
U937 cell lines were cultured in complete DMEM medium (Sigma), consisting of 10% 
v/v FBS, 2mM L-glutamine, 100U/ml penicillin (Sigma-Aldrich), 100µg/ml 
streptomycin (Sigma-Aldrich) and 1mM sodium pyruvate (Sigma-Aldrich), were left to 
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grown in 37ºC incubator with 5% CO2, until about 80% confluence of cells were 
reached. Cells were washed twice in PBS and adjusted to 5 x 105 cells in 12 well 
plates and left to adhere overnight in AIM serum free medium (Sigma-Aldrich). Cells 
were washed in PBS before addition of rhSP-D (10μg/ml) in AIM serum free medium 
containing 10mM HEPES buffer in total volume of 300μl for 1h at room temperature. 
In parallel, rhSP-D (10μg/ml) in AIM serum free medium containing 10mM HEPES 
buffer was incubated with MOI 1 of pH1N1 virus for 1 h at room temperature, to allow 
binding.  Properdin incubated with pH1N1 was then added to cells in a circular 
motion (total volume of 500μl). Pandemic H1N1 was added to cells that were pre-
incubated with properdin (total volume 500μl), and then incubated for 1h at room 
temperature. Cells were washed before the addition of 1 X infection medium (1ml 
total volume). Supernatants and cells were collected at different time points (15, 30, 
45 min, 1 h, 2 h, 6 h, 12 h, 24 h and 48 h) and subjected to multiplex cytokine array 
analysis. 
2.18. Multiplex cytokine array analysis 
Cytokines (IL-6, IL-8, IL-10, IL12p40, IL12p70, IL-23, IL-27, IL-1α and IL-1β) and 
chemokines/growth factors (MIG, I-TAC, MCP-1, G-CSF and M-CSF) concentrations 
in the supernatants of U937 cells were measured by MagPix Milliplex kit (EMD 
Millipore). Supernatants collected from the above-mentioned experiments were 
stored at -80°C until use. Briefly, 25µl of assay buffer was added to each well of a 
96-well plate, followed by addition of 25µl of standard, controls or supernatants of 
(rhSP-D treated) cells, to appropriate wells. 25µl of magnetic beads coupled to 
analytes were added in each well, and incubated for 18h at 4˚C. After washing the 
plate with assay buffer, 25µl of detection antibodies were incubated with the beads 
for 1h at RT. 25µl of Streptavidin-Phycoerythrin was then added and incubated for 
30’. Following a washing step, 150µl of sheath fluid (BD Biosciences) was added to 
each well and the plate was read using the Luminex Magpix instrument.  
2.19. Aspergillus strains 
48 clinical isolates of Aspergillus being 18 strains of fumigatus (AF), 10 strains each 
of niger (AN), flavus (AFL) and terreus (AT) were used in the study. Susceptibilities 
were determined using the microdilution procedure of the CLSI M38-A standard. 
Culture medium was RPMI 1640 + 2% glucose, inoculum 1 x 105/mL, plates 
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incubated for 24 hours at 37C; the plates were read both visually and on a 
spectrophotometer at 490nm (rhSP-D range 0.9273-15mg/l and 12.5-200mg/l for 
Gly-X-Y and delta rhSP-D, respectively). In a second set of experiments involving 3 
isolates of AF and one each of AN, AFL and AT, growth curves were determined in 
similar conditions with readings taken every 5 minutes for 24 hours ( 1.5-24mg/l). 
Susceptibility tests were performed on 48 clinical Aspergillus isolates; 18 A. 
fumigatus (AF), 10 isolates each of A. flavus (AFL), A. terreus (AT) and niger (AN). 
For growth rate assays 3 strains of AF and one strain each of AFL, AT and AN were 
used. 
2.20. Susceptibility testing 
Inoculum suspensions were from day 5 to 8 day cultures grown on Sabouraud 
dextrose agar at 37°C and adjusted to a final inoculum was between 5 x 104 and 2.5 
x 105 CFU/ml. Readings were done after 24 h of incubation at 37°C both visually and 
by spectrophotometer at 490nm. The MIC end-points were recorded as the lowest 
drug concentration that prevents any discernible growth. In the growth rate assays, 
microdilution plates were set up in similar conditions but with a dose range of 1.5-
24mg/l. Readings taken every 5 minutes for 24 hours. All Aspergillus isolates had 
reduced growth with Gly-X-Y in a dose dependent fashion. MIC values and MIC50 
were lower for A. niger than any other species. 40/48 strains demonstrated <80% 
reduction in growth at 15mg/l with MIC50 of 15, 1.875, 15 and 7.5 for AF, AN, AFL 
and AT, respectively.  
2.21. Preparation and labelling of conidia 
Spores and culture filtrate were obtained from the 285 strain of A. fumigatus isolated 
from sputum of an allergic bronchopulmonary patient who had been diagnosed 
based on Rosenberg criteria. Cultures were maintained on Sabouraud dextrose agar 
slants. Conidia were allowed to swell in phosphate- buffered saline (PBS) containing 
Ca2+ and Mg2+ for one hour being used for binding, agglutination, phagocytosis, 
oxidative burst and killing assay. Conidia were labelled by incubating 108 conidia 
with a 3 mg/ml stock of fluorescein isothiocyanate (FITC, sigma Chemical co.) in 0.5 
M carbonate buffer, pH9.0 for 18 hours at 4°C in the dark and with mild agitation. 
The labelled conidia were washed twice. The conidia remained viable after labelling. 
Following 1 h  pre-incubation, as previously reported by Schaffiner et al. was carried 
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out to stimulate the natural conditions of conidia since they are wetted by mucous 
secretions in the respiratory tract. 
2.22. Binding of rhSP-D to A. fumigatus conidia  
A.fumigatus was grown on Sabouraud dextrose agar slants at 37°C.The conidia or 
spores were harvested after 72 hours, washed twice in pyrogen-free saline, and 
stored in pyrogen- free saline. For interaction studies, 106 conidia were washed 
twice in filtered PBS containing 1% bovine serum albumin (BSA) and 5 mM CaCl2 
(PBS-BSA-Ca2+) at pH 7.4 and centrifiguated at 8, 000 x g for 10 minutes at 4°C. 
The conidia was then suspended in 100 µl of PBS-BSA-Ca2+ and incubated with 
various concentrations of SP-A and SPD for an hour at 37°C.  For inhibition studies, 
conidia were incubated with surfactant proteins in the presence of 10 mM EDTA, 100 
mM mannose, and 100 mM maltose. The conidia- surfactant complex were then 
washed twice with 200 µl of PBS-BSA-Ca2+ and incubated with 100 µl of rabbit anti-
human SP-D antisera (1:20 dilution) for an hour at 4°C.  After further washing as 
descried previously, the conidia were incubated with goat anti-rabbit Ig FITC- 
labelled antibody (1:50 dilution) for an hour at 4°C and washed again. The conidia 
were fixed with 2% (w/v) paraformaldehyde in PBS. Conidia- associated 
fluorescence was analysed by flow cytometry on a Becton Dickinson FACScan with 
Lysis II software. In control preparations, conidia were incubated with rabbit pre-
immune sera and FITC-labelled antibody to assess background fluorescence. 
2.23. Agglutination assay 
A. fumigatus conidia were washed twice in PBS-BSA-Ca2+ buffer and centrifuged at 
3,000 x g for 10 minutes at 4°C. The conidia (105 cells) were then re-suspended in 
100 µl of buffer containing rhSP-D at concentration between 1 and 5 µg/ml in 
siliconized tube (to avoid adherence to the tube walls), incubated at 37°C for an 
hour, and observed by phase- contrast microscopy. A Zeiss MC camera containing 
Kodak Tri-X Pan 400 ASA black- and white film was used to photograph the 
agglutination of the spores in size changes due to agglutination by dot plot analysis 
of cell forward and side scatter by employing a flow cytometer. 
2.24. Killing assay      
The percentage killing of the A. fumigatus conidia in presence of rhSP-D by the 
PMNs was assessed by the colorimetric MTT assay (Madan et al, 1997). Control 
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wells containing the PMNs alone were taken as negative controls, while wells 
containing conidia alone were taken as positive controls. 
2.25. Murine models 
Male BALB/c mice (National Institute of Nutrition, Hyderabad, India), weighing 20–22 
g each, were housed in polycarbonate shoebox cages. Mice fed on a standard 
laboratory rodent diet and had water ad libitum. Mice were immunosuppressed by 
three intradermal injections of 2.5 mg/(mouse day) (125 mg/kg body weight) of 
hydrocortisone acetate (Wycort) 1 day before, on the day, and the day after conidia 
challenge, as described previously (Madan et al., 2001a). 
2.26. Study design summary 
Various groups of mice each were selected and randomised. On the day 0, mice 
were lightly anaesthetised with ether and 108 conidia of Afu in 50 l sterile PBS were 
administered intranasal in the IPA group of mice and 50l  of PBS alone in the 
untreated Control mice. The groups of untreated Control and untreated IPA mice 
received 50l PBS alone intranasal on day 1. Mice were sacrificed from each group 
on days 2 and 4 following conidia challenge. 
2.27. Measurement of cytokine and chemokine levels in the 
lung cell suspension 
In the case of ABPA mice, the model was generated and characterised on various 
immunological parameters in the laboratory of Dr Taruna Madan, CSIR Institute of 
Genomics and Integrative Biology, Delhi, India using protocol described by Madan et 
al, 2001. For the eosinophil peroxidase assay (EPO), lung cell suspension (200 
μl/well) was plated in a 96-well tissue culture plate and incubated in a humidified CO2 
incubator at 37°C for 48 hours. The medium was aspirated and o-phenylene diamine 
(OPD) was added (100 μl of 1 mM solution was prepared using sterile PBS 
containing 0.1% v/v Triton X-100 and 0.0125% vol/vol H2O2). After 30-minute 
incubation at room temperature, the color reaction was terminated by addition of 50 
μl of 4 N H2SO4, and the A490 was measured. A portion of the lung tissue from 
sacrificed animals was minced, the cells were suspended in RPMI-1640 culture 
gentamicin (2 × 106 cells/well), and cultured for 72 h. The supernatants from the lung 
59 
 
suspension were assayed for IL-4, IL-5, TNF- -
Endogen, Cambridge, MA, USA and R&D. Each cytokine assay was performed twice 
in triplicate and the final values represent average ± standard deviation of 4 data 
points (4 animals of each group). 
2.28. Dendritic cell preparation 
Monocytes were obtained from either buffy coat (National Blood Centre, Oxford), or 
on few instances, from voluntary blood donors for which ethical approval has been in 
place at the Brunel University laboratory. Cells were grown in RPMI medium 1640, 
supplemented with 2 mM glutamine/50 μg/ml of kanamycin/1% non-essential amino 
acids (GIBCO/BRL)/1% pooled human AB serum, 50 ng/ml each of IL-4 (specific 
activity > 2 × 106 units/mg) and granulocyte macrophage–colony-stimulating factor 
(GM-CSF) (specific activity > 1 × 107 units/mg, Schering-Plough) for 6 days, or in 
serum-free XVIVO-15 medium (BioWhittaker) supplemented with 50 μg/ml 
kanamycin and the cytokines listed above. At day 6 of culture, non-adherent 
immature DCs were harvested and depleted of contaminating lymphocytes with the 
aid of magnetic beads (Milteny biotech) and anti-CD3 and anti-CD19 mAb (DAKO).  
For maturation assays, 1 × 106 purified DCs were incubated with or without 25 
μg/ml of isotype-control, test monoclonal antibody, or with SP-A or SP-D, for at least 
3 h at 37°C. DCs were then matured with either 100 ng/ml of LPS (Salmonella 
typhimurium, Sigma), 50 ng/ml of TNF-α, 1 μg/ml of soluble chimeric CD40L (Alexis) 
for 48 h or left untreated as a control. All maturation assays in the presence of SP-A 
or SP-D were performed in parallel in RPMI (with serum) and X-VIVO15 medium 
(without serum), both supplemented with GM-CSF and IL-4.  
2.29. Flow Cytometry  
The following antibodies directed against the respective human surface markers 
were used: these markers include CD3, HLA A,B,C, CD14, CD54, CD19 (Dako); 
CD80, CD40, CD86, HLA-DR (Serotec), CD83 (PharMingen). Staining of DCs was 
performed and analyzed by using a flow cytometer (Becton Dickinson). Dead cells 
were excluded from analysis by using PI.  
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2.30. T-Cell Proliferation Assays  
PBMCs were isolated following standard procedure and re-suspended in serum free 
medium containing RPMI, 2% FCS, Penicillin/Streptomycin and Sodium Pyruvate. 
Cells were stimulated with Phytohaemagglutinin (PHA) at a concentration of 1µg/ml 
and 100,000 cells (100µl) and aliquoted per well in a 96 well tissue culture plate. 
Next, the cells were treated with SP-A or SP-D in their respective wells. At the 72 h 
time point 3H-thymidine was added and the plate was pulsed for 16hours. Cells were 
harvested using a semi-automated cell harvester and the amount of 3H-thymidine 
incorporated into DNA was measured using a liquid scintillation counter. Each 
condition was carried out. 
With experiments involving T cell clones, DCs were added in increasing numbers up 
to 1 × 105 T cells and incubated for 5 days. We added 0.5 μCi 3H-thymidine/well for 
the last 18 h of the culture. For clonal T cell responses, 1 × 106 DCs were pulsed for 
6 h with known peptide after maturation. In these experiments, increasing numbers 
of MHC class II-sharing DCs were then incubated with 3 × 104 T cells for 72 h. 
Proliferation was measured as above. 
2.31. ELISA for supernatant cytokine measurement   
Supernatants from DC cultures under the conditions described were collected 24 h 
after addition of LPS, when TNF-α, IL-12, and IL-10 were at plateau levels. 
Supernatants from proliferation assays of the T-cell clone were collected after 60 h of 
culture. The concentrations of IL-4, IFN-γ, TNF-α, IL-12p70, and IL-10 were 
measured according to the manufacturer's specifications (R & D Systems). 
2.32. Statistical Analysis  
The relative increase in surface marker expression was calculated by dividing the 
mean fluorescence intensity (MFI) of LPS-exposed DCs by the MFI of immature DCs 
after subtracting values obtained with isotype-control antibody. Likewise, the 
cytokine concentrations in the supernatants of LPS-matured DCs were divided by 
those of immature DCs after subtracting background values with medium alone. In 
either case, the increases from at least three independent experiments were 
compared by using a paired-sample Student's t test.  
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3. Chapter 3 

























SP-A and SP-D perform innate immune functions in and outside lungs. SP-A and 
SP-D deal with various pathogens via agglutination/aggregation, enhancement of 
phagocytosis and killing. SP-A and SP-D are capable of linking innate immunity with 
adaptive immunity such as modulation of DC maturation and function, and helper T 
cell polarization. Here, we have examined the nature of interaction between rhSP-D 
and a common respiratory viral pathogen i.e. Influenza A Virus (IAV), and 
subsequent immunological consequences/outcomes. 
SP-A and SP-D can induce viral neutralization and enhanced uptake by phagocytes. 
SP-A and SP-D inhibit hemagglutinin (HA) binding activity of IAV (Benne et al, 1995; 
Hartshorn et al, 1994a). SP-D also interferes with neuraminidase (NA) activity 
(Reading et al, 1997). SP-D binds via its CRD region to mannosylated NA and HA 
(Hartshorn et al, 2000; Hartshorn et al, 1994b). H1N1 IAV strains are resistant to the 
neutralization by SP-A (Job et al, 2010).  SP-A can also interact with herpes simplex 
virus type1 (HSV-1) via its N-linked oligosaccharides and enhance phagocytosis by 
alveolar macrophages (van Iwaarden et al, 1992; van Iwaarden et al, 1991). SP-A 
binds F protein of RSV and neutralizes the virus (Sano et al., 1999 ; Hickling et al, 
1999 ; Ghildyal et al, 1999 ; Sano et al, 2003). SP-D binds to the attachment protein 
G and inhibits RSV infection in vivo and in vitro (Hickling et al, 1999). RSV-infected 
bronchiolar epithelial cell line express reduced SP-A protein levels (Bruce et al, 
2009). SP-A binds to HIV-1 gp120 and inhibits infection of CD4+ cells, but also 
enhances the transfer of infection to CD4+ T cells mediated by DCs (Gaiha et al, 
2008). SP-D inhibits HIV replication (Meschi et al, 2005). SP-D recognizes the SARS 
coronavirus spike glycoprotein (Leth-Larsen et al, 2007) and has also been found to 
bind bovine strains of the non-enveloped rotavirus (Leth-Larsen et al, 2007; Harrod 
et al, 1999). 
It is estimated that infection with seasonal strains of IAV results in the death of 
250,000 to 500,000 people and cause five million cases of severe illness per year. 
Young children, pregnant woman and elderly are more susceptible groups. Recently, 
the world has experienced major zoonotic transmission to humans of two different 
types of IAV (Galloway et al, 2013). Establishment and spread of highly pathogenic 
avian H5N1 IAV in birds and coincident infections in humans since 2003 have raised 
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concerns that we may be facing influenza pandemic (Loeffelholz and Chonmaitree, 
2010). Recently, a new swine-origin H1N1 IAV identified in April 2009 (Miller et al, 
2013) spread worldwide and was officially declared pandemic in June 2009. There 
are concerns that H1N1 or H3N2 viruses reassert with existing H5N1 virus in birds or 
pig intermediate host giving rise to more pathogenic viruses. The threat is the 
potential emergence of a highly pathogenic pandemic virus, as it has already 
happened in 1918 with a deadly IAV of H1N1 subtype, which killed about 50 million 
people during a two-year period (Miller et al, 2013). It is crucial to understand 
molecular mechanisms of host defense against IAV in order to design novel 
strategies to fight against this pathogen. As described earlier, collectins SP-A and 
SP-D play an important anti-viral role during IAV infection (Hartshorn, 2010). These 
collectins, expressed in the lung and in a variety of mucosal and epithelial surfaces 
in the body, are involved in a wide range of immune functions including 
neutralization, agglutination, opsonisation and clearance of pathogens. SP-A and 
SP-D have been involved in viral inactivation and aggregation (Hartshorn et al, 
1994b),  enhancement of phagocytosis by macrophages (Hartshorn et al, 1994), 
enhancement of neutrophil superoxidative burst (Hartshorn et al, 1997; Hartshorn et 
al, 1996). SP-D has been involved in recognition, neutralization and clearance of 
respiratory viruses (Nayak et al, 2012). Mice lacking either SP-A or SP-D show 
higher IAV replication, inflammation and mortality rates (LeVine et al, 2001; Zhang et 
al, 2002) . In these mice instillation or overexpression of rat SP-D restores anti-viral 
functions. 
Multimerization of human SP-A and SP-D is important for their anti-viral activities 
(Hartshorn et al, 1996).  Recently, investigators have shown that substitution of 
arginine343 with alanine amino acid in the CRD region enables a truncated trimeric. 
Human SP-D has been shown to mediate viral uptake by neutrophils and monocytes 
and to potentiate neutrophils respiratory burst responses (Hartshorn, 2010). Cross-
linking of truncated mutated human SP-D with specific monoclonal antibodies could 
mimic multimerisation and enhanced viral aggregation (Hartshorn, 2010). N-linked 
oligosaccharides on the HA and NA envelope glycoproteins of IAV are recognized by 
CRD region of SP-A and SP-D. Glycans exposed on the globular head of HA, which 
greatly vary in location and numbers between IAV strains, are responsible for this 
interaction (Wagner et al, 2000 ; Abe et al, 2004). Recently, the role of glycosylation 
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on the head of H1 subtype IAV in modulating sensitivity to SP-D in vitro and 
virulence in mice has been analyzed (Tate, Brooks and Reading, 2011). For this 
study, site-directed mutagenesis was used to add or delete specific glycosylation 
sites on H1HA and produce reassortant viruses. HA glycosylation profile, and mainly 
HA Asn 144, was shown to be a critical factor in sensitivity to SP-D, neutralization by 
mouse lung fluids and disease in mice. In addition to agglutination and opsonisation, 
binding of collectins to HA and NA also inhibit HA-dependent early stage of infection 
in vitro and NA activity (Tecle et al, 2007), respectively. However, the exact 
mechanism of IAV inhibition by collectins is not yet fully understood. SP-D and 
mannose binding lectin (MBL) seem to inhibit early phases of IAV infection by 
blocking viral uptake and/or HA-mediated fusion (Tecle et al, 2007 ; Leikina et al, 
2005). SP-D mediated agglutination may also contribute to reduction of infectious 
particle numbers (Hartshorn et al, 1994a).  In this study, we wish to better 
characterize the molecular mechanisms of neutralization of IAV by rhSP-D. 
3.2.   Results 
3.2.1. Expression in E. coli, purification and characterization of 
a recombinant fragment of human SP-D (rhSP-D) 
composed of neck and CRD region. 
The recombinant human surfactant protein (rhSP-D) was expressed and purified in 
E.coli as described in the methods and materials (section 2.3). Following 
transformation, a pilot expression was carried out to examine the presence of rhSP-
D. Samples were collected before and after induction with IPTG (figure 3.1) for 
3hours and run as described in (methods section) on a SDS-PAGE gel as shown 
below in (figure 3.1) in order to visualize the presence of rhSP-D, which was 
confirmed by the presence of rhSP-D band at ~20kD as also previously 
demonstrated by (Mahajan et al., 2008). After successfully expressing rhSP-D, the 
time course of IPTG needed to be ascertained in order to find out the optimum time 
point at which there is the greatest induction with IPTG. This was achieved by 
removing samples at various time points after induction, varying from 0 hrs to 5 hrs, 
where the sample was collected after each hour. The samples obtained after each 
rime point were loaded onto an SDS-PAGE gel as shown below in (figure 3.1). From 
the gel the best protein expression can be observed three hours after induction with 
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0.4 mM IPTG, where the rhSP-D accumulated as an over-expressed protein of ~20 
kDa. 
Upon confirmation of rhSP-D protein expression, the protein was subsequently 
purified as described in (Method section). The refolded protein, obtained after 
stepwise urea dialysis, was passed through affinity chromatography column 
(containing Maltose Sepharose) which was also prepared as also described in 
Chapter 2. The eluted fractions were collected in 1.5ml Eppendorf tubes and an 
SDS-PAGE gel was run as shown below in (figure 3.1). To show the presence of 
purified rhSP-D protein as shown below. From SDS–PAGE gel it appears that the 
highest protein concentrations were eluted into first five fractions. 
Bacterial LPS was removed by following the method described, where the purified 
rhSP-D protein was passed through a column containing, Polymyxin B agarose gel. 
Following endotoxin removal the LPS free rhSP-D fractions were pooled together 
and SDS–PAGE (15% w/v) was run as shown below in (figure 3.2) to further confirm 
the presence of purified rhSP-D after LPS removal.  
 The BCA Protein Assay was used as described in Chapter 2 (section 2.9.) for the   
colorimetric detection and quantitation of total protein following the purification of 
rhSP-D. The amount of protein was also further quantified by measuring the UV 
absorbance at 280 nm. The highest fractions from each of the purified batches were 
pooled together separately and then prepared using BCA protein assay reagent, as 
detailed in (section 2.9.) of materials and methods Chapter 2. The OD values were 
than determined at 562 nm for both batch 1 and batch 2 pooled samples and were 
found to be at 1.33 and 1.18, respectively. The protein concentration of each sample 
was then determined by extrapolation using the plotted standard curve for BSA. 
From the graph, it was determined that the concentration for batch 1 was 
approximately 1.3mg/ml, whereas the concentration for batch 2 was found to be 
approximately 1.1 mg/ml. 
The endotoxin level in the protein preparation was assessed by QCL-1000 Limulus 
amoebocyte lysate system (Lonza). The assay was linear over a range of 0.1–1.0 
EU/ml (10 EU=1ng of endotoxin). From the standard graph obtained, a line of best fit 
was drawn and an equation was derived for this line of best fit. Thus from this 
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equation, an approximate value for endotoxin content was estimated in the purified 
rhSP-D preparation, which was found to be in the region of 2.965EU/ml. 
Since previous cross-linking studies have indicated that rhSP-D exists predominantly 
as a trimer in solution, a BS3 Cross-linking Assay, as described under materials and 
methods, was carried out in order to observe the trimerization of rhSP-D. As it can 
be seen below in (Fig 3.1) the rhSP-D was incubated with various concentrations of 
BS3 cross linker in order to determine the best concentration of BS3 cross-linker, 




Figure 3.1 SDS- PAGE (15%) showing rhSP-D, which was expressed as inclusion bodies using 
Escherichia coli BL21 (DE3) pLysS. After 3 hours of induction with IPTG, the rhSP-D over-expressed 
as evident by  20 KDa band. a) Lanes 1,3,5,7,9 b) Lanes 2,4,5 compared with uninduced cells a) 





Figure 3.2 SDS–PAGE (12% w/v) analyses of rhSP-D and rh Bovine conglutinin after purification. 
Cross-linking of protein interactions among themselves to know if they form dimers and trimers to 
confirm the interactions using the non-cleavable NHS-ester cross-linker bissulfosuccinimidyl suberate 
(BS3) in dose-dependent manner (0.5, 1 and 10 mM BS3 concentrations respectively). 
 
3.3.    rhSP-D binds IAV in solid-phase direct binding ELISA 
Since rhSP-D was able to inhibit haemagglutination of IAV, we set out to establish 
possible interaction of rhSP-D with HA and NA using H3N2 envelope proteins. The 
recombinant rhSP-D bound envelope comprising hemagglutinin and neuraminidase 
proteins in a dose- and calcium-dependent manner, suggesting the importance of 
glycosylation and CRDs in this interaction (figure 3.3). The direct binding ELISA data 
was validated by far-western blot that established protein-protein interaction between 
rhSP-D and IAV proteins (figure 3.4). These binding data appear to suggest that 
direct interaction of rhSP-D with H3 and N2 proteins is likely to either interfere or 





Figure 3.3 Interaction between rhSP-D and H3N2 in a direct binding ELISA. The rhSP-D in constant 
5ug/100ul/well dilution was coated overnight at 4 degree C° using multi-sorb plates. The following 
day, blocking of the non-bound sites with 2% BSA in PBS was performed. Following extensive 
washing with PBS, H3N2 was added at different dilutions in PBS (10ul, 5ul, 2.5ul, 1.25ul, 0.625ul) per 
well. The virus was left to incubate with the proteins at 37 degrees for 1.5 hours. The excess un-
bound virus was washed off using PBS. A polyclonal primary antibody, goat anti-human anti-Udorn 
antibody, against the virus was used at a dilution of 1:5000 and added to each of the wells. Following 
incubation for 1 hour at 37 degrees C, excess antibody was washed off with PBS and the secondary 
antibody (anti-goat protein A conjugated to horseradish peroxidase) was added to the wells. After 
incubation for one hour at 37 degrees C, the excess secondary antibody was washed off and the 












Figure 3.4 Binding of H3N2 virus with rhSP-D. H3N2 virus (2 dilutions) was denatured and viral 
proteins were separated by SDS-PAGE. The blot was probed with anti-H3N2 polyclonal antibodies, or 
with rhSP-D (10μg/ml). Purified H3N2 virus was run on SDS-PAGE, and H3N2 viral proteins were 
detected using anti-Udorn antibodies. rhSP-D binds H3N2 virus proteins, when probed with anti-
human SP-D polyclonal antibodies (1:5000). (B) Pure H3N2 was run on gel and probed with Anti-





Figure 3.5  Cell biniding assay: The rhSP-D inhibits H3N2 interaction with THP-1 cells. Wells were 
treated with Poly L-Lysine and THP-1 cells (50,000) per well were added in serum free conditions 
After blocking with 2% w/v BSA for 1 hour at 37 degrees C. A 1/10 dilution of the virus was used as 
40 l in 400 l total (50,000 pfu/l). In one set of experiments, virus was pre-incubated with rhSP-D 
(20 (grey), 10 (brown) and 5 (green) g) for 1 hour at room temperature and added to the THP-1 cells 
(D). In the second set, cells were pre-treated with rhSP-D for 1 hour at room temperature and then 
challenged with virus (E). Virus alone (A) and BSA as a control protein (B) and (C) were used as 
negative control. Excess virus was washed with cold PBS; cells were fixed with Paraformaldehyde, 
washed with PBS again, and then blocked for 1 hour in PBS/BSA. Primary anti-H3N2 antibody in PBS 
was added, and then washed with PBS. The secondary antibody IgG HRP in PBS was used as a 












3.4. Multiplex cytokine array analysis showed 
downregulation of pro-inflammatory cytokine TNF-a and IL-6 
by rhSP-D treated virus 
To understand the immune response following viral challenge against THP-1 cells, 
H3N2 (A/Hong Kong/99) virus was incubated with rhSP-D at MOI 1 (THP-1) and 
supernatant was collected at 24 and 48 h time points (Figure 3.6) and subjected to 
multiplex cytokine/chemokine array analysis. Cytokines (IL-6, IL-8, IL-10, IL12p40, 
IL12p70, IL-23, IL-27, IL-1α and IL-1β) and chemokines/growth factors (MIG, I-TAC, 
MCP-1, G-CSF and M-CSF) concentrations in the supernatants of THP-1 cells were 
measured by MagPix Milliplex kit (EMD Millipore). Cells were incubated with rhSP-D-
bound and unbound IAV, spun down at 300g, and supernatants were stored at -80°C 
until use. Briefly, 25µl of assay buffer was added to each well of a 96-well plate, 
appropriate wells. 25µl of magnetic beads coupled to analytes were added in each 
well, and incubated for 18h at 4˚C. After washing the plate with assay buffer, 25µl of 
detection antibodies were incubated with the beads for 1h at RT. 25µl of 
Streptavidin-Phycoerythrin (PE) was then added and incubated for 30 min. Following 
a washing step, 150µl of sheath fluid (BD Biosciences) was added to each well and 
the plate was read using the Luminex Magpix instrument.  
Most cytokines and chemokines did not show any considerable alteration in their 
secreted levels. However, there was an important downregulation of TNF-α and IL-6 
in the instance where IAV was pre-treated with rhSP-D (figure 3.6), suggesting that 
the presence of rhSP-D inhibited production and secretion of these two crucial pro-




Figure 3.6 Multiplex cytokine array analysis of supernatants of THP-1 cells treated with rhSP-D 
bound or unbound IAV (following 24hour challenge). Changes shown in fold compared to THP-1 cells 
alone. The Yaxis represents the amount of cytokines in pg/ml. 
3.5.    Discussion 
It is estimated that infection with seasonal strains of IAV results in the death of up to 
0.5 million people and caused 5 million cases of severe morbidity per year. Young 
children, pregnant woman and elderly are more susceptible groups. Recently, the 
world has experienced major zoonotic transmission to humans of two different types 
of IAV (Galloway et al, 2013). Establishment and spread of highly pathogenic avian 
H5N1 IAV in birds and coincident infections in humans since 2003 have raised 
concerns that we may be facing influenza pandemic (Loeffelholz and Chonmaitree, 
2010). Recently, a new swine-origin H1N1 IAV identified in April 2009 (Miller et al, 
2013) spread worldwide and was officially declared pandemic in June 2009. There 
are concerns that H1N1 or H3N2 viruses re-assort with existing H5N1 virus in birds 
or pig intermediate host giving rise to more pathogenic viruses. The threat is the 
potential emergence of a highly pathogenic pandemic virus, as it has already 
happened in 1918 with a deadly IAV of H1N1 subtype, which killed about 50 million 
people during a two-year period (Miller et al, 2013). It is crucial to understand 
molecular mechanisms of host defence against IAV in order to design novel 
strategies to fight against this pathogen.  
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Pattern recognition receptors and soluble factors of innate immunity play a very 
important role in modulating viral infection and subsequent cellular response to viral 
recognition and intracellular existence. Locally synthesized soluble humoral factors 
such as SP-D are likely to play a far important role in dealing with IAV in the lungs. 
Thus, we examined a likely interaction of a truncated SP-D molecule that has 
previously been well characterized biochemically, biophysically, inn vitro and in vivo 
using with various strains of IAV.  
Initially, a range of IAV strains were selected based on their pathogenesis, epidemic 
history and pandemic features. These strains were subjected to a simple but 
powerful hemagglutination assay using guinea pig RBCs which are normally 
agglutinated by viral incubation in a titre dependent manner. Molecules or factors, 
which inhibit viral attachment to RBCs reduce the degree of agglutination. We then 
used direct binding ELISAs using pandemic H3N2 strain to examine if rhSP-D could 
interact directly with virus via its two most important envelope proteins and virulence 
factors. In order to identify viral proteins globally that would interact with rhSP-D, 
protein-protein interaction studies via far western blotting were carried out in which 
virus was run on an SDS-PAGE and transferred blot was probed with rhSP-D. As a 
positive control, the same blot was probed with anti-Udorn antibodies that would 
recognize all viral proteins. We also examined the immune response of THP-1 cells 
following viral challenge in the presence or absence of rhSP-D. Our results 
demonstrate a direct interaction between rhSP-D and human IAV viruses of diverse 
H3N2 subtypes. In the case of H3N2 pre-incubation of rhSP-D with IAV led to 
downregulation of TNF-II and IL-6h, compared to virus alone challenge. This, 
coupled with inhibition of IAV binding to THP-1 cells, suggests that rhSP-D is able to 
recognize HA and NA differentially due to varying levels of carbohydrate sialic acid 
and charge patterns. This is an area that needs further investigation. It is likely that 
rhSP-D will interfere with TLR IAV interaction given reduced production of TNF-α.  
In summary, rh SP-D by virtue of being produced or present locally in the lungs is 
capable of modifying host-IAV interaction. This interaction between IAV and rhSP-D 
restrains virus replication in target cells. Currently, we are hoping to identify the exact 
step of the virus life cycle affected by rhSP-D such as virus binding, endocytosis, and 
viral RNA uncoating, and consequences for pathogenesis and stimulation of the host 




4. Chapter 4 





















4.1.  Introduction 
Aspergillus fumigatus (Afu) is a major airborne fungal microorganism with 
manifestations dependent on the host’s immune status. A. fumigatus is an 
opportunistic pathogen, which causes allergic disorders in the immuno-competent 
host such as allergic rhinitis, allergic sinusitis, hypersensitivity pneumonitis, and 
allergic bronchopulmonary aspergillosis (ABPA). Invasive pulmonary aspergillosis 
(IPA) occurs frequently in immunocompromised or immunosuppressed patients, 
notably in patients with cystic fibrosis, AIDS and asthma, and often proves fatal 
despite treatment with antifungal drugs. Aspergillus spp. is the major fungal 
pathogens in immunocompromised, and neutropenic patients with mortality rates in 
excess of 50% in treated patients. Despite advances in antifungal therapy mortality 
rates following invasive aspergillosis even after treatment remain unacceptably high. 
Alternative approaches to therapy are therefore required. Infection with A. fumigatus 
is characterized by presence of both type I and type III hypersensitivity reactions 
leading to increased levels of total IgE, specific IgE (A. fumigatus- IgE), specific IgG 
(A. fumigatus-IgG), and blood and pulmonary eosinophilia (Patterson, 1998). In the 
absence of adequate host immunity, as in severely immunocompromised or 
neutropenic patients, because of chronic glucocorticoid treatment, AIDS, aplastic 
anaemia, or chemotherapy-induced neutropenia (Sternberg, 1994), A. fumigatus 
disseminates to other tissue causing systemic and fatal form of disease, called 
invasive apergillosis, characterised by hyphal invasion and destruction of pulmonary 
tissue. 
Alveolar macrophages and recruited neutrophils are considered to clear A. fumigatus 
from the lung, which appears to be principal portal of entry of this pathogen 
(Bardana,E.J.,Jr 1982). Neutrophils, various macrophages and polymorphonuclear 
cells (PMNs) can kill A. fumigatus conidia and damage hyphae (Schaffner, 1982; 
Levitz, 1986; Roilides. 1993). When exposed to A. fumigatus conidia in vitro, cells of 
macrophage lineage secrete TNF-α and IL-1 (Taramelli, 1996) as well as cytokines 
that promote a Th1 response (Grazziutti, 1997).  However, A. fumigatus conidia can 
be resistant, to some degree, to reactive oxygen intermediates generated during 
phagocyte stimulation (Bardana, 1982). 
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Both SP-A and SP-D bound to carbohydrate structures on A. fumigatus conidia in a 
calcium- dependent manner, causing agglutination of the conidia and enhancing the 
binding of conidia to alveolar macrophages and neutrophils (Madan, 1997) (figure 
4.1). Furthermore, in the presence of SP-A and SP-D, phagocytosis, oxidative burst 
and killing of conidia were significantly increased by neutrophils (figure 4.2). These 
findings strongly suggest that SP-A and SP-D may have an important immunological 
role in the early anti-fungal defense in the lung, through inhibiting infectivity of 
conidia by agglutination and by enhancing uptake and killing of A. fumigatus by 
phagocytosis. Mice model of IPA intranasally given therapeutic SP-D showed higher 
survival following a fatal challenge with A. fumigatus conidia, as evident from with 
lower CFU counts, diminished hyphal growth, and elevated lung IFN- and TNF- 
(figure 4.3) (Madan,T. 2001). Intranasal administration of rhSP-D was protective in a 
murine model of invasive pulmonary aspergillosis both, in terms of reduced organ 
burden and improved survival. When a range of full-length and truncated SP-D 
proteins was given therapeutically to the IPA murine model, 10 g was found to be 
optimal for the observed protective effects (Singh et al, 2009). 
SP-D gene-deficient (SP-D−/−) mice were also more susceptible to IPA, while SP-A 
gene-deficient (SP-A−/−) mice acquired resistance to IPA (Madan et al., 2010), 
suggesting that SP-A may facilitate pathogenesis by A. fumigatus. A. fumigatus-
challenged SP-A-/- mice showed less mortality (40%) than the wild-type mice (100%) 
and increased mortality (60%) following administration of SP-A with decreased TNF-
α and IFN-γ to IL-4 ratio than SP-A-/- IPA mice. The SP-D-/- IPA mice (57.14%) 
showed similar mortality as wild-type mice (60%). However, the SP-D-/- IPA mice 
(42.86% mortality on day 2) died earlier than the WT-IPA mice (20% mortality on day 
2), showed a higher hyphal density and tissue injury in lungs (fig 4.5). Treatment with 
SP-D or rhSP-D fragment reduced the mortality to 50 and 33%, respectively, 
consistent with higher IFN-γ to IL-4 ratios in treated SP-D-/- mice, compared to 
untreated control group. The results showed that SP-D-/- mice are more susceptible 
to IPA while SP-A gene-deficient mice acquire resistance to IPA (Madan et al., 
2010). 
In addition, SP-D can also interact, via their carbohydrate recognition domains 
(CRDs), with the carbohydrate residues present on the allergens/antigens of A. 
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fumigatus and interfere with IgE-mediated release of histamine by sensitised 
basophils (Madan,1997). In the present study, we have expressed and extensively 
characterized a recombinant fragment of human SP-D (rhSP-D), composed of 
trimers of the neck region and carbohydrate recognition domains, in E. coli and 
examined whether this truncated form of human SP-D retains the immunomodulatory 
properties displayed by full-length SP-D against A. fumigatus. The rhSP-D bound A. 
fumigatus conidia and enhanced its phagocytosis by polymorphonuclear cells 
(PMNCs). The rhSP-D could also inhibit the binding of A. fumigatus-IgE to the 
allergens/ antigens from the three-week culture filtrate (3wcf) of A. fumigatus and 
blocked subsequent histamine release from sensitized basophils, isolated from a 
murine model of ABPA. The rhSP-D also suppressed the lymph proliferation of 
mouse splenic cell cultures of ABPA mice. Following incubation with the rhSP-D, the 
splenic supernatants of the ABPA mice showed a significant decrease in the levels 
of IL-4 and IL-5 (characteristic of a Th2 response) and an increase in the levels of 
IFN- (Th1 response), whereas an increase in the levels of TNF- in the case of IPA 
mice was observed. These results suggest that even a truncated form of rhSP-D, 
lacking collagen and N-terminal regions, can have a significant immunomodulatory 
effect against A. fumigatus in vitro and implicate trimeric CRDs of human SP-D as a 
self-sufficient molecule. In addition, we have also compared two variants of rhSP-D: 
one contains 8 Gly-X-Y repeats of the collagen region (called Gly-X-Y rhSP-D) and 
the other is only neck and CRD region (called rhSP-D delta). We found that both 




Figure 4.1 Agglutination of A. fumigatus conidia before and after incubation with SP-A or SP-D at two 
concentrations of the proteins. SP-D appear to cause massive agglutinates compared to SP-A, 
probably due to its cruciform structure as well as ball-like overall multimeric structures. BSA as a 





Figure 4.2 Killing of A. fumigatus conidia by alveolar macrophages. Germinated hyphae appear 
resistant when exposed to macrophages alone. However, the presence of SP-A or SP-D in the 
presence of calcium for 60 minutes appears to fragment the hyphae of Aspergillus fumigatus. The 





Figure 4.3 The survival percentage of the IPA mice over 15 days after challenge with 10
8
 spores of A. 
fumigatus on day 0 and treatment with PBS, Amphotericin B, SP-A, SP-D, and rhSP-D on day 1 
(Madan et al, 2001). Empty and filled Squares represent Amphotericin B and rhSP-D treatment; 
empty circles represent SP-D treatment; while triangles and diamonds represent SP-A and untreated 





Figure 4.4. The protective effect of various doses of full-length and truncated SP-D in an IPA model. 
The survival percentage of the IPA mice over 15 days following challenge with (10
8
) A. fumigatus 
conidia on day 0, and then treated with PBS; (A) full-length human SP-D and (B) a rhSP-D) (5, 10 or 




Figure 4.5 Mortality in various groups of mice. Mice were immunosuppressed with corticosteroid prior 
to an intranasal challenge with A. fumigatus conidia. (A) SP-A gene deficient mice (SP-A
−/−
) mice and 
(B) SP-D gene deficient (SP-D
−/−
) mice compared with their respective wild type (WT) mice. The bar 
graphs depict the lung CFU counts isolated from the above-mentioned groups on day 2 of the study 
(Madan et al, 2010)  
 
4.2.  Result 
4.2.1. The rhSP-D can bind A. fumigatus conidia and enhance 
its phagocytosis and killing by PMNs 
The rhSP-D showed dose-response binding to conidia in the presence of calcium 
which could be inhibited by EDTA or maltose, indicating involvement of the CRD. 
When FITC labelled conidia were incubated with leukocytes in the presence of rhSP-
D there was a dose responsive increase in uptake of spores with a 3-fold increase 
observed at 5 g/ml. A 2.5-fold increase was observed for native human SP-D. The 
positive control of autologous serum (10%) also resulted in a 2.5 fold increase in 
mean fluorescence intensity.  
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The rhSP-D showed a dose responsive increase in killing of conidia by phagocytosis. 
As expected, phagocytes alone brought about killing (42.36%), but this was 
increased 2-fold by the addition of 5 g/ml rhSP-D which was similar to that reported 
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Figure 4.6 Direct binding of solid-phase conidia to rhSP-D with and without sugar and calcium. A. 
fumigatus conidia (10
8
) was coated on maxisorb microtitre wells overnight and then blocked with 2% 
BSA in PBS. rhSP-D was added to the wells for 2 hrs at RT and allowed to bind the spores with and 




































 s p o r e s  +
P M N s  +
rh S P -D
0 .5  g /m l
 s p o r e s  +
P M N s
 s p o r e s  +
P M N s  +
rh S P -D
1 .0  g /m l
 s p o r e s  +
P M N s  +
rh S P -D
5 .0  g /m l
 s p o r e s  +
P M N s  +
1 0 %
a u to lo g o u s
s e r u m
 
Figure 4.7 Percentage killing of A. fumigatus by PMNs at various concentrations of rhSP-D as 
measured by MTT colorimetric assay, as in Madan et al, 1997a. 
 
4.2.2. Binding of rhSP-D to 3wcf allergens/antigens can block 
IgE-induced histamine release from sensitised basophils 
The allergens/antigens of A. fumigatus showed a calcium dependent and dose 
responsive binding similar to that of native human SP-D. The inhibition of binding 
with 10 mM EDTA and 100 mM maltose indicated that the CRD region were 
responsible for binding to the glycosylated allergens and antigens in the 3wcf. The 
inhibition of the binding of A. fumigatus specific IgE to 3wcf allergens by rhSP-D is 
shown in figure 4.8. The rhSP-D mediated IgE binding inhibition was dose 
responsive, with over 70% inhibition at 5 g/ml compared to over 90% inhibition 
observed with native human SP-D at 5 g/ml. The sensitised basophils extracted 
from the whole blood of  these mice showed a 3-fold decrease in histamine release 
in the presence of 5g/ml rhSP-D, which was as in the same range as seen with 
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Figure ‎4.8 Binding of rhSP-D to 3wcf allergens/antigens of A. fumigatus in the presence of various 
concentrations of rhSP-D with and without its inhibitors, EDTA and mannose. rhSP-D bound to 
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Figure 4.9 rhSP-D inhibits IgE binding to immobilized 3wcf antigens/allergens. A. fumigatus 3wcf (5 
ug/ml)) was coated on maxisorb microtitre wells overnight and then blocked with 2% BSA in PBS. 
rhSP-D was added to the wells for 2 hrs at RT and allowed to bind the allergens for 2 hr in the 
presence of 1/10 dilution of ABPA patients’ pooled sera. Anti-human IgE conjugated to HRP was then 
used to assess the level of IgE binding to allergens. The pooled sera derived from ABPA patients 
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Figure 4.10 Suppression of histamine release by rhSP-D by sensitised basophils.(1)10µg/ml 3wcf. (2) 
10µg/ml 3wcf+ 0.5 µg/ml rhSP-D.(3)10µg/ml 3wcf+ 1µg/ml rhSP-D.(4)10µg/ml 3wcf+ 5 µg/ml rhSP-D. 
 
4.2.3. The rhSP-D can alter cytokine profile of murine ABPA 
splenocytes 
A significant increase in A. fumigatus-IgG and A. fumigatus-IgE levels was observed 
in the groups of mice immunised for four weeks with 3wcf, in comparison to those of 
controls immunised with PBS alone (significantly different at p>0.05). The ratio of 
peripheral blood eosinophil counts of the sensitised mice was higher compared to 
the control groups of non-sensitized mice. Pulmonary eosinophilia picture was 
similar to that of peripheral blood eosinophilia. Histopathological findings revealed 
that mice in control groups had normal bronchi and parenchyma with a few 
eosinophils. Animals exposed to 3wcf showed extensive chronic inflammatory 
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infiltrates, mainly representing lymphocytes, plasma cells, and eosinophils. These 
inflammatory cells were frequently located around perivascular and peribronchiolar 
areas. The levels of eosinophile peroxidase assay (EPO) activity in the lung 
suspensions of mice immunised with 3wcf were elevated markedly in comparison 
with the mice of control groups on day 0 of the study.  The ratio of EPO activity in 
test versus control mice of group A on day 0 was observed to be 1.752 which 
gradually came down to 1.220 on 16th day. Ratios of IL-2, IL-4, IL-5 and IFN- levels 
in splenic supernatants of the sensitized mice to controls were observed to be 2.744, 
5.469, 1.750 and 0.663, respectively. 
The splenocyte cytokine profile produced by 3wcf antigens was characteristic of a 
Th2 response due to raised levels of IL-4 and IL-5. The addition of 5 g/ml rhSP-D 
brought about a decrease in IL-4 and IL-5 and an increase in IFN- in the splenocyte 
supernatants, which is more consistent with a Th1 response. Addition of rhSP-D 
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Figure 4.11 Cellular infiltration and splenic cytokine profiles in the ABPA mice. (a) The cellular 
infiltration is quite evident in the three-week culture filtrate treated mice compared to mice that 
received only intranasal PBS. Most of the infiltrates are neutrophils and eosinophils. (b) Cytokine 
levels in pg/ml of IL-4, IL-5 and IFN-γ of various mice (ABPA), observed in 72 h splenic supernatants 
with or without treatment with rhSP-D. 
 
4.2.4. Expression and purification of a recombinant fragment 
of human SP-D without any collagen extension in the 
construct (rhSP-D delta) 
Two recombinant variants of human SP-D (rhSP-D Gly-X-Y and Delta) composed of 
homotrimeric neck and carbohydrate recognition domains were expressed in E. coli 
and purified by a procedure involving denaturation-renaturation, ion-exchange, 
affinity and gel-filtration chromatography, similar to as done for the Gly-X-Y 
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containing rhSP-D described in Chapter 2. The Gly-X-Y variant contains additional 8 
Gly-X-Y triplets from the collagen region of SP-D whereas the Delta variant lacks any 
additional residue at its N-terminus of the neck region (figure 4.12). A ~18 kDa 
protein (28 residues of alpha-helical neck region and 125 residues of CRD region of 
human SP-D) was produced after induction with IPTG and visualised on an SDS-
PAGE under reducing conditions. This was found to be the major protein in the 
insoluble inclusion body pellet after centrifugation of the cell lysate. The pellet readily 
dissolved in 6 M Urea and initial purification by anion exchange chromatography 
removed most of the other bacterial proteins. The acetone precipitation step had the 
surprising effect of increasing the recovery of rhSP-D delta after refolding by 5-fold. 
After the refolding steps, maltose-agarose affinity chromatography selectively bound 
functionally active rhSP-D delta which after washing with 1M NaCl was eluted with 
EDTA. Final purification by ion exchange yielded a pure and homogenous 
preparation of trimeric homotrimeric rhSP-D delta (figure 4.12). The yield was 10 
mg/L of induced bacterial culture. 
 
 7              6          5            4          3           2           1     Lanes 
Figure 4.12 Expression and purification of the rhSP-D delta. Gel 1: SDS-PAGE (15% w/v) analysis of 
ΔrhSP-D after dialysis against HEPES buffer under reducing conditions showing only monomer at 
18KDa. Lane 1: Protein marker; Lane 2: 2.5µl of dialyzed ΔrhSP-D; Lane 35µl of dialyzed ΔrhSP-D; 
Lane 4: 7.5µl of dialyzed ΔrhSP-D; Lane 5: 10µl of dialyzed ΔrhSP-D; Lane 6: 15µl of dialyzed ΔrhSP-




In order to get whole ranges of spectrum showing monomer, dimer and trimer band 
using particular concentration of cross linker in SDS-PAGE, the dialyzed ΔrhSP-D 
was incubated with varying the incubation time with Bissulfosuccinimidyl 
suberate (BS3). 5µl of 0.1mM concentration of BS3 was incubated with 45 µl of the 
dialysate for 1 min, 2 min, 4 min, 8 min, 16 min and 18 min at room temperature. The 
cross-linking reaction was electrophoresed on a 15 % (w/v) SDS-PAGE gel under 
reduced conditions after adding equal volume of treatment buffer to each time point 
and stored at room temperature. Later boiled the samples together in the heating 
block for 7 minutes, then stained and de-stained. Upon reaction with cross-linking 
agent at various incubation time higher oligomers such as monomer (18 KDa), dimer 
(~40 KDa), and trimer (~ 60 KDa) were seen (figure 4.13). 
 
 
                                     Lanes    5          4        3         2        1 
Figure 4.13 SDS-PAGE 15 % (w/v) gel under reducing conditions in the presence of BS3 and stained 
with Coomasie blue. Lane 1: protein marker Lane 2: 5 µl of 0.01mM BS3 and sample incubated for 0 
min; Lane 3: 5 µl of 0.01mM and sample incubated for 1min; Lane 4: 5 µ of 0.01mM and sample 
incubated for 2min; Lane 5: 5 µl of 0.01mM BS3 and sample incubated for4 min l 
 
4.2.5. Fungistatic properties of the two variants of rhSP-D 
48 clinical isolates of Aspergillus being 18 strains of A. fumigatus, 10 strains each of 
A. niger, A. flavus and A. terreus were used in the study. Susceptibilities were 
determined using the micro-dilution plate modification of the CLSI (formerly NCCLS) 
M38-A standard. Culture medium was RPMI 1640 + 2% glucose, inoculum 1 x 
92 
 
105/mL, plates incubated for 24 hours at 37C; the plates were read both visually and 
on a spectrophotometer at 490nm (rhSP-D) 
Susceptibility tests were performed using the broth micro-dilution modified method of 
CLSI M38-A using RPMI 1640 medium buffered to pH 7.0 with MOPS and 2% 
glucose. In brief drug ranges (in mg/L) for rhSP-D were 0.9237, 15mg/L and 
12.5mg/L for Gly-XY and Delta rhSP-D, respectively. Inoculum suspensions were 
from day 5 to 8 day cultures grown on Sabouraud dextrose agar at 37°C and 
adjusted to a final inoculum was between 5 x 104 and 2.5 x 105 CFU/ml. Readings 
were made after 24 h of incubation at 37°C both visually and by spectrophotometer 
at 490nm. The MIC endpoints were recorded as the lowest drug concentration that 
prevents any discernible growth. In the growth rate assays, micro-dilution plates 
were set up in similar conditions but with a dose range of 1.5-24mg/L. Readings 
taken every 5 minutes for 24 hours.  
All Aspergillus isolates had reduced growth with Gly-X-Y in a dose dependent 
fashion. MIC values and MIC50 were lower for A. niger than any other species. 
40/48 strains demonstrated <80% reduction in growth at 15mg/L with MIC50 of 15, 
1.875, 15 and 7.5 for AF, AN, AFL and AT respectively. 
rhSP-D Gly-X-Y substantially reduces the growth rate of Aspergillus spp. in vitro. The 
inhibitory activity of Gly-X-Y is superior to that of the Delta variant. The main 
antifungal activity can be localized to the lectin domain. This demonstrates an 
additional mechanism by which this innate immune molecule protects against fungal 
infection.  
With Gly-X-Y rhSP-D, all isolates showed reduced growth in a dose dependent 
fashion. 40/48 strains demonstrated <80% reduction in growth at 15g/mL with 
MIC50s of 15, 1.875, 15 and 7.5 for AF, AN, AFL and AT respectively.  With Delta 
rhSP-D, less inhibition occurred with 35/38 strains showing reduced growth over the 
dose range. 80% reduction in growth was seen in few isolates (5/48 strains). In the 
growth rate assays, all strains demonstrated both an overall reduction in growth rate 
(as measured by increasing OD) in a dose dependent fashion. Reduction in growth 
rate was most clearly seen by increased lag time (time until the OD increased) which 




rhSP-D Gly-X-Y substantially reduces the growth rate of Aspergillus spp. in vitro. The 
inhibitory activity of Gly-X-Y is superior to that of the Delta variant. The main 
antifungal activity can be localized to the lectin domain. This demonstrates an 
additional mechanism by which this innate immune molecule SP-D substantially 
reduces the growth rate of Aspergillus in vitro and this fungistatic activity can be 
localized to the lectin domain. This is an additional mechanism by which SP-D 
provides protective immunity without involving phagocytes. Thus, the rhSP-D may be 
used as a potent barrier to fungal infection.  
  Gly-X-Y rhSP-D Delta rhSP-D 
 n Range MIC50 Range MIC50 
A fumigatus 18 3.75->15 15 200->200 >200 
A niger 10 1.875-3.75 1.875 200->200 >200 
A flavus 10 15->15 15 200->200 >200 
A terreus 10 3.75-15 7.5 200->200 >200 
 
Table 4.1 Gly-X-Y rhSP-D showed reduced growth in a dose dependent fashion. Delta rhSP-D, less 
inhibition occurred with 35/38 strains showing reduced growth over the dose range (n= number of 
samples). 
  
   Gly-X-Y rhSP-D Delta rhSP-D 
 n Range MIC50 Range MIC50 
A fumigatus 18 0.469-15 0.469 12.5- >200 50 
A niger 10 0.469-0.938 0.938 12.5- >200 200 
A flavus 10 0.469-3.75 0.469 12.5- >200 100 
A terreus 10 0.469-1.88 0.468 50 >200 100 
 
Table 4.2 Gly-X-Y rhSP-D showed reduced growth in a dose dependent fashion. Delta rhSP-D, less 







Figure 4.14 Reduction in growth rate was clearly seen by increased lag time (time until the OD 




Aspergillus fumigatus can cause allergic and invasive aspergillosis depending on the 
host’s immune status (Varkey, 1998). In the immunocompetent host, it causes 
allergic disorders, such as allergic rhinitis, allergic sinusitis, hypersensitivity 
pneumonitis, and ABPA. In the immunocompromised host, A. fumigatus 
disseminates to other tissue causing systemic and fatal IPA or IA. Bronchiectasis 
and cystic fibrosis also allow colonization of A. fumigatus. Aspergillus infection is 
rising due to increased chemotherapy due to cancer and organ transplantation. 
Dissemination of Aspergillus infection to other organs occurs in about 20% of the IPA 
cases (Denning, 1990). In spite of correct diagnosis and treatment, IPA results in 
mortality of >80% patients. The mortality rate among patients following bone marrow 
transplantation can be as high as 95% (Sternberg, 1994). Alveolar macrophages and 
peripheral blood polymorphonuclear and mononuclear phagocytes are considered to 
form the major host defense against A. fumigatus. Macrophages have been shown 
to participate in the early phase of defense by ingesting inhaled, airborne Aspergillus 
conidia and inhibiting their intracellular germination. In addition, PMN and circulating 
monocytes also cause damage to escaping hyphae (late phase of defense) by 
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secreting microbicidal oxidative metabolites and non-oxidative compounds, thus 
preventing establishment of invasive disease (Schaffner, 1982). Suppression of 
innate immunity by immunosuppressive drugs results in lowering of essential 
defence barriers against invasive aspergillosis (Sternberg, 1994). The phagocytic 
activity of the peripheral blood monocytes-derived macrophages and the anti-fungal 
activity of neutrophils against A. fumigatus from HIV-infected children have been 
shown to be significantly decreased as compared to normal donors (Roilides, 1993a; 
Roilides, 1993b). Treatment for the invasive form of aspergillosis, to provide 
complete cure, is complicated by the chemotherapy of allergic patients with steroids 
and of chronically infected patients with aggressive anti-fungal drugs, which have 
highly adverse side effects, such as hepatotoxicity and nephrotoxicity.  
Recently, involvement of SP-D in the initial protective immunity against A. fumigatus 
infection has been shown (Madan et al, 1997a). SP-D has an anti-fungal role in the 
lung, by inhibiting infectivity of conidia via agglutination and enhancing uptake and 
killing of A. fumigatus by recruited phagocytes. 
The rhSP-D binds to A. fumigatus conidia in calcium-, dose- and carbohydrate-
dependent manner. Most excitingly, the phagocytosis and killing of conidia by PMNs 
were found to be enhanced almost 3-fold by rhSP-D. Nagai et al have reported 
protective effect of exogenous TNF- and IFN- in a murine IPA.  Rollides et al have 
shown enhancement of phagocytosis of Aspergillus conidia by rabbit alveolar 
macrophages in the presence of 10 ng/ml of TNF-. Intratracheal challenge of both 
cyclophosphamide-treated and untreated mice with A. fumigatus conidia leads to the 
increased levels of TNF- in the lungs. Antibody neutralisation of elevated TNF- 
resulted in an increased mortality in both normal as well as cyclophosphamide-
treated mice. Depletion of TNF- also resulted in a reduced lung neutrophil influx, 
decrease in the lung levels of macrophage inflammatory protein-2 (MCP-2) and 
macrophage inflammatory protein-1 (MCP-1) (Mehrad, 1999). TNF-, therefore, 
appears to be a critical component of innate immunity in anti-Aspergillus defense.  
The murine model of ABPA, used in the present study to examine the effect of rhSP-
D on IgE inhibition, histamine release, lymphoproliferation and cytokine profile, 
exhibited peripheral blood and lung eosinophilia, elevated A. fumigatus-IgE and A. 
fumigatus-IgG levels and Th2 type cytokine profile, as described previously (Kurup, 
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1992; Wang, 1998). Mast cells release, after cross-linking of bound IgE to A. 
fumigatus allergens, a variety of pro-inflammatory mediators, which induce bronchial 
smooth muscle contraction and vascular permeability. In ABPA, the A. fumigatus-IgG 
and A. fumigatus-IgE bind Fc receptors present on eosinophils, leading to secretion 
of inflammatory mediators (Varkey, 1998). The rhSP-D bound the antigens/allergens 
derived from 3wcf, in sugar and calcium specific manner and inhibited the binding of 
A. fumigatus-IgE to these allergens, and blocked histamine release from the 
sensitised basophils. The binding of allergens/antigens of A. fumigatus is likely to 
reduce their availability to cross-link the IgE present on the surface of eosinophils 
and mast cells.  
Elevation of the levels of A. fumigatus- IgG, an important diagnostic criterion for 
ABPA, is a reflection on the Th2 response of the host to A. fumigatus antigens 
(Varkey, 1998). Th2 lymphocytes can induce IgE synthesis, eosinophil recruitment 
and activation. We also observed an increase in the levels of IL-4, IL 2 and IL-5 and 
decrease in the level of IFN-II in the splenic supernatants of ABPA mice, indicating 
predominance of Th2 cells on prolonged exposure to A. fumigatus antigens (Chu, 
1996; Kurup, 1992; Kurup, 1994). IL-5 has been implicated in recruitment of 
eosinophils and maturation of pulmonary eosinophils, since neutralization of IL-5 by 
anti-IL-5 antibody has been shown to abrogate the peripheral and pulmonary 
eosinopilia in the murine ABPA (Murali, 1993). An increased IL-4 levels in the splenic 
supernatants appeared to correlate with IgE levels seen in the serum, suggesting 
that IL-4 could be a major modulator of IgE production in murine ABPA. Stimulation 
of T cell proliferation (Knutsen, 1994) and basophil hyper reactivity with increased 
histamine release has also been reported in ABPA. IL-4 also induces expression of 
VCAM-1 on vascular endothelial cells and its ligand VL-4 on T cells and eosinophils, 
in addition to inducing eotaxin and recruits eosinophils to the site of antigen 
(Bonecchi, 1998). Presence of IL-4 during the priming of naive T cells has been 
shown to be critical for the development of a Th2 response. In our model, increased 
levels of IL-2 is likely to support clonal expansion of A. fumigatus-specific Th2 cells 
since IL-2 and its receptor play a crucial role in the growth and differentiation of 
many cells such as T and B lymphocytes, NK cells, macrophages and monocytes. 
The lower level of IFN-II in the splenic supernatants of ABPA mice is suggestive of a 
Th2 CD4+ T cell response (Kurup, 1994) which leads to a hypersensitivity pulmonary 
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lung disease. When splenocytes were treated with rhSP-D, the splenic supernantant 
of the sensitized mice showed decrease in the levels of IL-4 and IL-5 (Th2 type) and 
increase in IFN-II (Th1 type) levels. IFN-III, a Th1 type cytokine, promotes the 
cellular immunity. It is believed that Th1 CD4+ T cell response is protective against 
A. fumigatus.  
SP-D has been shown to inhibit the PHA and CD3-stimulated lymphoproliferation of 
PBMCs of normal individuals (Borron, 1998), and also allergen induced proliferations 
of PBMCs of asthmatic children sensitive to mite allergens (Wang, 1998). The rhSP-
D has suppressive effect on the lymphoproliferation of sensitised mouse splenic 
cells. Since histamine release and lymphocyte proliferation are two essential steps in 
the development of asthmatic symptoms, this recombinant form of truncated SP-D 
(rhSP-D) appears to be a potential therapeutics towards the control of allergen-
induced disorders. Several recent reports indicate that the CRD regions of SP-D may 
fulfil other functions besides binding carbohydrate structures. It has been 
demonstrated that the CRD region of SP-D is chemotactic for neutrophils (Cai, 
1999). A putative receptor molecule for SP-D, described as gp-340, has been shown 
to bind the CRD region (Holmskov, 1997), as opposed to SP-A receptor molecules 
which appear to bind to collagen region of SP-A. The recombinant form of truncated 
SP-D (rhSP-D) could potentially be used for the treatment of A. fumigatus infections 









5. Chapter 5 
Modulation of Dendritic Cell Maturation and 
























A population of adherent cells was initially identified as a requirement for the 
induction of B and T cell responses in vitro and in vivo (Steinman and Cohn, 1973; 
Steinman, Adams and Cohn, 1975; Steinman, Lustig and Cohn, 1974; Steinman and 
Cohn, 1973).  
5.1.1. Origin and distribution of dendritic cells   
DCs are found as immature cells in virtually all organs (except the brain) within the 
interstitial spaces, and mucosal surface, which is highly well developed in the lungs 
(Karre and Welsh, 1997), in addition to being present in the heart, kidney, dermis, 
liver, and other organs. 
DCs display differences in anatomic localization, cell surface phenotype, and 
function (Banchereau and Steinman, 1998; Hart, 1997). DCs originate from CD34 
bone marrow stem cell; precursor DCs home to tissues where they become 
immature DCs, which can take up antigen and present via class II MHC II molecules 
in order to interact with antigen-specific CD4 T cells to initiate immune responses 
(De Smedt et al, 1997; Kalinski et al, 1998; Kuroda et al, 2000; Liu et al, 1997; 
Staquet et al, 1995; van der Pompe et al, 1998; Vieira et al, 2000). Distinct 
chemokine receptors occur on immature and mature DCs (Cyster, 1999; Homey and 
Zlotnik, 1999; Sallusto and Lanzavecchia, 1994; Zlotnik and Yoshie, 2000). IL-12 
produced by DCs helps in the activation of naïve CD4 + T cells and their 
engagement with Th1 cells (Vieira et al, 2000). Monocytes from spleen, blood, or 
bone marrow can potentially generate conventional DCs (Naik et al, 2006).  
5.1.2. Human Dendritic cells  
DCs mature in lymphoid and non-lymphoid tissues (figure 5.1) (Cerio et al, 1989). 
LCs and interstitial DCs evolve from CD34+ bone marrow and CD11c+ blood 
precursors in the presence of GM-CSF and IL-4/TNF-α (Caux and Prost, 1999; 
Romani et al, 1994; Sallusto and Lanzavecchia, 1994). Upon activation by CD40L, 
immature myeloid DCs undergo maturation and produce IL-12 (Cella et al, 1996). 
(Caux and Prost, 1999; Romani et al, 1994; Sallusto and Lanzavecchia, 1994; Zhou 
and Tedder, 1996). LCs and interstitial DCs share several markers, but LCs uniquely 
express CD1a, Birbeck granules, langerin, and the adhesion molecule E-cadherin. 
Interstitial DCs express the coagulation factor XIIIa (Caux et al, 1997 ; Caux and 
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Prost, 1999). Plasmacytoid DCs (pDCs) are found in the T cell zones of lymphoid 
organs, thymus and blood (Facchetti, Candiago and Vermi, 1999; Grouard et al, 
1997; Res et al, 1999; Sorg, Kogler and Wernet, 1999). pDCs are characterized by a 
unique phenotype and secrete IFN-α/β upon viral challenge (Cella et al, 1999; 
Grouard et al, 1997; Kohrgruber et al, 1999; Siegal et al, 1999; Grouard et al, 1997; 
Kohrgruber et al, 1999). pDCs can also activate CD4 and CD8 naïve T cells and 
secrete IL-12 (Cella et al, 2000 ; Kohrgruber et al, 1999). 
5.2. Dendritic cells maturation: The link between Innate and 
Adaptive Immunity 
There are endogenous and exogenous factors that affect DCs and their ability to 
direct T cell phenotypes- anergic, memory, or effector (Lipscomb and Masten, 2002). 
LPS, peptidoglycans, and microbial DNA enhance the T cell stimulation via DCs 
through TLRs, which lead to DC maturation (Kaisho and Akira, 2001). TNF-α 
(Sallusto et al, 1995) as well as cellular heat shock proteins (Basu and Srivastava, 
2000) also promote DC maturation and T cell effector function (figure 5.2). IL-10, IL-
1α, 25-dihydroxyvitamin D3, ligands to CD36 or CD51, and cAMP-elevating agents, 
suppress DC function (figure 5.5) (Buelens et al, 1995; Sato et al, 1999; Penna and 
Adorini, 2000; Urban, Willcox and Roberts, 2001; Kambayashi, Wallin and 
Ljunggren, 2001). Thus, the ability of DCs to initiate an appropriate immune defense 
is critically dependent on signals present in the local microenvironment (figure 5.3) 









Figure 5.1 DC subsets derived from CD34
+
 myeloid and lymphoid progenitors. GM-CSF, TNF-α, 
IL-4, TGF-β, and IL-3 are modifiers of this differentiation. The precursor cells are vastly influenced by 
cytokine and growth factors in the tissue microenvironment. The maturing cells further undergo 
differentiation based on their residency that includes interstitial DCs, Langerhans DCs, and 
plamacytoid DCs. Due to the availability of a number of surface markers and antibodies to 














Figure 5.2 The migratory and maturation pathways of DCs. As mentioned above, GM-CSF, TNF-
α, IL-4, TGF-β, and IL-3 are modifiers of DC differentiation. The precursor cells are influenced by 
cytokine and growth factors in the tissue microenvironment. The maturing cells further undergo 
differentiation based on their residency that includes interstitial DCs, Langerhans DCs, and 
plamacytoid DCs. Following their relocation to draining lymph nodes, the IL-12 cytokine dictates their 
differentiation into type I or type II DCs under the influence of PAMPs or prostaglandins. The 








Figure 5.3 Maturation and differentiation pathways of DCs and their involvement in cellular 
immune response. The danger signals reflecting on the pro-inflammatory stimuli can give rise to 
effector Th2 or Th1 phenotypes of T cells in the presence of non-self antigens. In the presence of self 
antigens, a regulatory phenotype is generated that leads to tolerance and non-inflammatory 








5.3. Role of DCs in Immune- mediated disease  
Inflammation is triggered by infection or tissue injury and is characterized by the 
secretion of inflammatory mediators, including cytokines and chemokines, and the 
massive recruitment of leukocytes, such as neutrophils and monocytes (figure 5.4) 
(Medzhitov, 2008). Following inflammation, monocyte derived DCs express HLA-DR, 
CD11c, BDCA1, CD1a, FcεRI, CD206, CD172a, CD14 and CD11b (Segura et al., 
2013 ; Wollenberg et al., 2002 ; Guttman-Yassky et al., 2007), in addition to M-CSFR 




Figure 5.4 Stimulatory and regulatory DCs have a wide range effect on the human cells in both 
health and disease conditions. The presence of IL-12 or IL-10 by DCs can dictate whether the T 
cell function will be pro-inflammatory or regulatory. Depending on this, these effector cells can cause 
pathogenesis. Thus, DC phenotype is of immense importance I the elimination of pathogens as well 













Figure 5.5 Co-stimulatory molecules and their ligands. The interaction between DC and T cells is 
dependent on signal 1 that originates due to interaction between peptide-loade MHC class II 
molecules and T cell receptors. In addition, interaction of PRRs such as TLRs overexpresses co-
stimulatory molecules on DCs that will have its cognate partner on T cells, thus yielding signal 2. In 
the absence of DC expression of co-stimulatory molecules, T cells become either apoptotic or anergic 
(Medzhitov, 2008). 
 
5.4. Modulation of DCs by SP-A and SP-D 
SP-A and SP-D regulate T cell proliferation (Wright and Youmans, 1993; Wright, 
2005). SP-A binds to DCs and negatively regulates their maturation in vitro, thereby 
reducing their T cell allo-stimulatory ability (Brinker, Garner and Wright, 2003). Datta 
et al have used mice deficient in SP-A in order to test the hypothesis that SP-A 
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regulates recruitment, activation, and maturation of adaptive immune cells in 
response to M. pneumoniae by regulating expression of the endogenous stress 
factor high-mobility group box-1 (HMGB-1), which, if released in the context of 
infection, can activate DCs and leads to their maturation (Datta et al, 2005).  Julie et 
al have reported in their article that M. Pneumoniae infection leads to increased 
numbers of exudative macrophages and DCs in the lung parenchyma, a response 
that is augmented by the absence of SP-A. Likewise, the total number and activation 
state of DCs that have migrated to the mediastinal draining lymph nodes during the 
acute phase of infection are also increased in the absence of SP-A. Additionally, 
elevated number of activated T and B cells in the lung and mediastinal lymph nodes 
(MLNs), as well as M. pneumonia, specific IgG in the serum, are observed in mice 
lacking SP-A after M. Pneumoniae infection (Julie et al, 2010). More DCs were found 
in the lung of M. pneumoniae infected mice that lacked SP-A, and more functionally 
mature DCs were detected in MLNs, where they would act as potent T cell 
stimulators. Additionally, MCP and MIP-1, factors known to be chemotactic for 
immature DCs (Napoli et al, 1996; Sallusto et al, 1995), were present in BAL fluid of 
infected mice at much higher levels in mice lacking SP-A, Suggesting that more DCs 
migrated into the lung from the blood stream of M. pneumoniae- infected mice in the 
absence of SP-A as a result of greater chemokine production. The amount of GM-
CSF, a factor vital to enhancing the differentiation of monocytes into immuno-
stimulatory DCs in the lung vascular, was significantly increased in BAL from wild 
type and SP-A null M. pneumoniae infected mice. Collectively, these findings 
suggested that, in the absence of SP-A, more DCs infiltrate the airways as a result of 
increases in chemo-attractant signals (Julie et al, 2010) 
SP-D also interacts with DCs to enhance uptake and presentation of bacterial 
antigens. SP-D augments antigen presentation by mouse bone marrow-derived DCs, 
but binds better to immature than mature DCs (Pfeifer et al, 1993; Svensson, 
Stockinger and Wick, 1997). SP-D enhances the antigen presentation of an 
ovalbumin fusion protein to ovalbumin- specific MHC II restricted T cell hybridoma 
(Brinker et al, 2001). Similar to SP-D ability to distinguish between immature and 
mature DCs, mannose receptor is highly expressed on immature DCs for enhancing 
internalization and antigen presentation of mannosylated antigens, but its expression 
on mature DCs is reduced (Engering et al, 1997; Sallusto et al, 1995). TLR-3 and 
107 
 
CD36 are highly expressed on immature DCs (Albert et al, 1998; Muzio et al, 2000). 
SP-D increases T cell IL-2 production by 5-fold when DCs are challenged with SP-D 
opsonized bacterial cells. Similarly, the efficiency of bacterial antigen presentation is 
increased by SP-D (Brinker, 2001).  
In this chapter, the effects of SP-A and SP-D on the maturation and immunologic 
functions of monocyte derived DCs were examined. The parameters included 
measurement of surface and co-stimulatory markers, secretion of cytokines and 
proliferative response of T cell clones, as described in Chapter 2 (Materials and 
Methods). 
5.5. Results 
5.5.1. Effect of SP-A and SP-D on LPS induce maturation of 
DCs 
When Salmonella LPS was used at 100 ng/ml concentration to induce maturation of 
the human monocytes derived immature DCs, the FACS profile of post-treatment DC 
markers dramatically altered in the presence of native human SP-A and SP-D, using 
medium alone as a negative control. To achieve this, monoclonal antibodies against 
DC maturation markers such as those against class II MHC molecules (HLA-DR), 
CD54, CD40, CD83, and CD86 were used. This range of markers covered for 
antigen presentation and co-stimulatory molecules. SP-A and SP-D were added 
three hours post LPS treatment at 10 µg/ml concentration. In medium + LPS, all five 
markers were up-regulated in response to LPS challenge, while SP-D had no effect 
(as if it was like medium control) on DC maturation. Curiously, SP-A was down 
regulating expression of DC maturation markers in the presence of LPS. In the case 
of HLA-DR and CD54, the down regulation was nearly 50% in the case of CD40, SP-
A suppressed surface expression only by 30%. However, in the case of CD83 and 





Figure 5.6 Salmonella LPS (100ng/ml):  Effect of SP-A and SP-D on LPS induce maturation of DCs. 
Salmonella LPS (100 ng/ml) was used to against immature DCs. Monoclonal antibodies against DC 
maturation markers such as those against class II MHC molecules (HLA-DR), CD54, CD40, CD83, 
and CD86 were used. SP-A and SP-D (10 µg/ml each) were added 3 h after LPS treatment. In 
medium + LPS, all five markers were up-regulated in response to LPS challenge, while SP-D had no 
effect (as if it was like medium control) on DC maturation. Curiously, SP-A was down regulating 
expression of DC maturation markers in the presence of LPS. In the case of HLA-DR and CD54, the 
down regulation was nearly 50% in the case of CD40, SP-A suppressed surface expression only by 
30%. However, in the case of CD83 and CD86, SP-A suppressed surface expression down to 
approximately 80%.     
 
5.5.2. Effect of SP-A and SP-D on TNF-α induce maturation of 
DCs           
In order to examine if the effect of surfactant proteins (SP-A, SP-D) on DC 
maturation was only exclusive to LPS, which is a ligand for SP-A and SP-D, as well 
as TLR, we carried out DC maturation experiment using human TNF-α at 50 ng/ ml 
concentration. TNF-α was used as pro-inflammatory cytokine, which is produced by 
macrophages and immature DC in response to stimulation by LPS. Although, TNF-α 
did not have effect on DC maturation as dramatic as that with Salmonella LPS still all 
five markers used were up-regulated. In this case the effect SP-D was either 
comparable to medium + LPS, or even more pronounced. Consistent with data from 
LPS stimulation in figure number 1, SP-A was able to suppress up regulation of this 
markers thus acting as inhibitor of DC maturation (figure 5.2). The effect of SP-A on 
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almost all maturation markers was more than 50% down regulation except in case of 
CD83, which was down 10 fold (figure 5.7). 
 
Figure 5.7 TNF-α (50 ng/ml): Effect of SP-A and SP-D on TNF-α induce maturation of DCs. DC 
maturation experiment was carried out using human TNF-α at 50 ng/ ml concentration. TNF-α did not 
have effect on DC maturation comparable to Salmonella LPS but most markers used were up-
regulated. Similar to the case with LPS, SP-A suppressed up- regulation of surface markers but SP-D 
had negligible effect. 
 
5.5.3. Regulation of LPS induced TNF-α secretion By SP-A and 
SP-D 
We also examined if immature DC produced TNF-α in response to challenge with 
Salmonella LPS, and if SP-A and SP-D modulated production of TNF-α secreted by 
immature DCs. DC alone, DC with SP-D, DC with SP-A secreted basal level of TNF-
α, that is less than 50 pg/ml. LPS induced up to 550 pg/ml of TNF-α, which was 
raised to 800 pg/ml by SP-D. Quite remarkably, SP-A down regulated TNF-α 





Figure 5.8 Effect of TNF-α: Regulation of LPS induced TNF-α secretion by SP-A and SP-D.  
Production of TNF-α by immature DC in response to Salmonella LPS was measured by ELISA. DC 
alone, DC with SP-D, DC with SP-A secreted comparable levels of TNF-α. SP-D raised cytokine 
production whereas SP-A down-regulated TNF-α production by 10-fold. 
 
5.5.4. Modulation of biologically active IL-12p70 by mature 
DCs  
Given that SP-D was not able to contain DC maturation in response to stimulation by 
LPS, TNF-α, and CD40L, it was considered that these two proteins may be 
influencing IL-12 production following DC maturation in a differential way. As clear 
from figure 5.9, DC on its own and either with SP-D or SP-A, did not produce above 
basal level secretion of IL-12 as measured by antibodies specific to p70 subunit. In 
response to LPS induced maturation, DCs produced very good amount of IL-12, that 
is, nearly 600 pg/ ml, which was further enhanced by SP-D (800 pg/ ml). Not 





Figure 5.9 Effect of IL-12p70: Modulation of IL-12 production by mature DCs. The effect of SP-A and 
SP-D on DC mediated production of IL-12 was examined via ELISA (anti-p70 subunit) using the 
supernatant/culture medium. Maturing DCs produced ~600 pg/ml of IL-12, was examined via ELISA 
(anti-p70 subunit) using the supernatant/culture medium. Maturing DCs produced ~600 pg/ml of IL-12, 
which was further enhanced by SP-D, whereas SP-A suppressed IL-12 production. 
 
5.5.5. Modulation of IL-10 production in the presence of SP-A 
and SP-D 
Given the ability of SP-A to down regulate DC maturation induced by LPS, TNF-α, 
and CD40L, and its ability to suppress TNF-α and IL-12 production, we wanted to 
assess the ability of SP-A and SP-D to modulate IL-10, a potent anti- inflammatory 
cytokine (figure 5.10). LPS induced near basal level of IL-10 expression with or 
without SP-D (nearly 200 pg/ml). However, SP-A up-regulated IL-10 production by 7 





Figure 5.10 Effect of IL-10: Modulation of IL-10 production in the presence of SP-A and SP-D. Given 
the ability of SP-A to down regulate DC maturation induced by LPS, TNF-α, and CD40L, and its ability 
to suppress TNF-α and IL-12 production, we wanted to assess the the ability of SP-A and SP-D to 
modulate IL-10, a potent anti- inflammatory cytokine. LPS induced near basal level of IL-10 
expression with or without SP-D (nearly 200 pg/ml). However, SP-A up-regulated IL-10 production by 





Figure 5.11 Proliferative allogenic T cell response by DC modulated by SP-A and SP-D: To examine 
if DCs maturation could affect T-cell proliferation in the presence of SP-A and SP-D, DCs were mixed 
with a varying ratio of T-cell clones (1:1000, 1:100, 1:10 DC: T cell ratio). After co-culturing 1:10 ratio 
gave the best proliferative response; cells were harvested 72 hours after thymidine pulse. DCs cause 
T cell proliferation up to 200,000 cpm, which was raised to 250,000 cpm in the presence of SP-D. 
However, SP-A was able to suppress proliferation of T-cell clones by 50%. The ‘y’ axis represents 
cpm x 10
3
. The grey bar represents medium alone, the while bar represents SP-D, while the black bar 
represents SP-A exposure to the co-culture system. 
5.6. Discussion 
SP-A and SP-D by virtue of being a pattern recognition soluble receptor has 
previously been shown to bind to a range of allergens derived from pollen grains, 
hosts mite, and Aspergillus fumigatus. under in vitro condition SP-A,  SP-D, and a 
recombinant fragment of human SP-D have been shown to bind to mite allergens 
and purified Derp I in a calcium and maltose dependent manner (Wang et al, 1996) 
this interaction between surfactant proteins and mite allergens also inhibited specific 
IgE binding to allergens derived from mite allergen sensitive patients. Subsequently, 
SP-A, SP-D, and rhSP-D were shown to bind Aspergillus fumigatus  allergens and 
antigens derived from 3wcf of mycelium, this interaction inhibited specific IgE and 
IgG to bind to allergens, which leads to suppression of histamine release buy 
sensitized basophiles derived from allergic bronochopulmonary aspergillosis patient 
(ABPA) (Madan et al, 1997). A murine model of pulmonary hypersensitivity that 
mirrored ABPA was then generated by first intranasal challenge with 3wcf followed 
by repeated dermal injection of the allergens stroke antigens within 4 weeks the 
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ABPA mice showed high levels of specific IgE and IgG in the serum, peripheral and 
pulmonary eosinophilia and heightened eosinophils peroxidase activity. Lung 
sections showed massive infiltration rich in poly-morphonuclear cells suggesting 
pulmonary inflammation. When the spleen cells were cultured and challenged with 
3wcf, supernatant were rich in Th2 cytokines (IL-4 and IL-5). When ABPA mice were 
given therapeutically SP-A, SP-D, or rhSP-D, only SP-D or rhSP-D treated mice 
showed a reduced level specific IgG, IgE suppressed bloody eosinophilia, down 
regulated EPO activity and spleen culture supernatants showed a shift from Th2 
cytokine profile to Th1 cytokine (IFN-γ) (Madan et al, 2001b). It was curious that SP-
A was not very effective at offering resistance to allergenic challenge, subsequently, 
mice genetically deficient in SP-A or SP-D were examined for the development of 
ABPA models (Madan et al, 2005a). When the gene deficient mice were intra-nasally 
and systemically treated with 3wcf as described in Madan et al 2001, the SP-A 
knock-out mice showed poor immunological response to allergenic challenge. In 
other words, mice were resistant to developing ABPA. The SP-D knock-out mice, on 
the contrary, showed dramatic phenotypes that included exaggerated pulmonary 
inflammation, hyper eosinophilia, increased IgG and IgE levels, and massive up 
regulation of IL-13. This was a very novel and exciting development in the field. It 
was well known that SP-D knock-out mice have characteristics of emphysema, 
foamy macrophages, hyperlipidaemia, and protienosis (Poulain et al, 1998). 
Curiously, IL-13 over expressing phenotype of mice also include increased phosphor 
lipid pool, foamy macrophages, type II cell hypertrophy, fibrosis, eosinophilia, 
inflammation emphysema and AHR. In addition to several, fold increase in levels of 
IL-5 and IL-13, and lowering of IFN-γ to IL-4 ratio in the lungs. This Th2 bias was 
reversible by treating knock-out SP-D mice with rhSP-D. Knock-out SP-D mice more 
susceptible than wild type mice to pulmonary hypersensitivity induced by A. 
fumigatus allergens. Intranasal treatment with rhSP-D rescues A. fumigatus-
sensitized knock-out mice.    
Here, we have investigated the effect of SP-A and SP-D on DC maturation and 
cytokines profile. SP-A and SP-D seem to have an opposite effect on DC although 
they belong to the same family (Collectins). SP-A can suppress phenotypic DC 
maturation induced by LPS and TNF-α. SP-A decreases the secretion of TNF-α and 
IL-12, and at the same time the production of IL-10 via SP-A modulation suggests an 
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anti-inflammatory role during allergic response and hence contribution to the 
eventual resolution of inflammation. IL-10 can also raise the threshold for maturation 
and antigen presentation by bystander DC at sites of inflammation and tissue injury.  
Moreover, SP-A discourages IL-12 during T cells activation as well as allogenic T 
cell proliferative response. Thus, by modulating DC, SP-A may be crucial in 
balancing pro-inflammatory motives of matured DC and that of SP-D. On the other 
hand, SP-D has no effect on the progression of DC maturation, and SP-D may have 
a Th1 bias through increasing the secretion of TNF-α and IL-12. Finally, SP-D can be 
considered as an excellent inducer of allogenic T cell proliferative response, in 
addition to its effect to facilitate IFN-γ production. 
It is evident that SP-A and SP-D are involved in homeostatic functions via balancing 
each other’s pro-inflammatory and anti-inflammatory properties. By acting at the 
level of DC via IL-12, a nice balance of helper T cell polarisation can be achieved. 
The data also suggest that IL-10 production in the presence of SP-A may raise the 
threshold of inflammatory response and bring about tolerogenic effects. It can be 
concluded that SP-D has a hierarchal role in protection against allergy and asthma. 
These stages include binding to allergens, inhibition of IgE binding to allergens, 
inhibition of histamine release, allergen presentation, IgE synthesis, eosinophil 
apoptosis and helper T cell polarisation. This study suggests a mechanism through 
which SP-D can cause Th1 polarisation, as reported previously in vitro and in vivo 











6. General Discussion and perspectives 
Pulmonary surfactant protein SP-A and SP-D seem to have a range of immune and 
non-immune functions. Their non-immune functions include maintenance of the 
surfactant recycling and surface tension in the expiring and inspiring lungs. A 
number of therapeutic properties have been assigned to a recombinant fragment of 
human SP-D that is composed of homotrimeric forms of coiled-coil neck region and 
the CRD (rhSP-D). This includes its protective role murine models of influenza A 
virus (IAV) infection, invasive pulmonary aspergillosis (IPA) and allergic 
bronchopulmonary aspergillosis (ABPA) (Kishore et al, 2002). However, how a small 
fragment of human SP-D brings about these effects is not very clear. This issue 
becomes more pertinent in the light of existing knowledge about the receptor 
complex calreticulin-CD91 that is known to bind to the collagen region of human SP-
D. A number of receptors and binding proteins have been described for the CRD 
region but their nature of interaction and pathophysiological significance remains 
uncertain (Kishore et al, 2006). Thus, this thesis sought to examine in vitro 
mechanisms via which rhSP-D offers therapeutic effects in the above-described 
murine models.  
The rhSP-D described in the literature contains a fortuitous segment of N-terminal 
collagen region of eight Gly-X-Y repeats (Kishore et al, 1996). It has been largely 
debated that this extension provides additional stabilising effect on the trimerising 
force exerted by the neck region. It is worth noting that the two crystal structures 
described at high resolutions have been unable to reveal the collagen region (Shrive 
et al, 2003). It is thus largely believed that the 8 Gly-X-Y regions in the rhSP-D 
molecule is unstructured. Furthermore, it is also important to recognise that E. coli 
(which is the host strain for expressing rhSP-D) does not have the post-translational 
machinery to generate hydroxyprolines that would be required for the triple-helical 
assembly of the collagen-like region of SP-D. Thus, it is not surprising that rhSP-D 
crystals do not show up collagen extension in the three-dimensional crystallographic 
symmetry, as revealed by two high quality crystal structures published by Shrive et al 
(2003; Shrive et al, 2008). However, to address this issue further, we generated a 
new construct that include only neck and CRD region of human SP-D. Since in this 
construct, the 8 Gly-X-Y region was removed, we called it delta rhSP-D. 
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We report here that rhSP-D binds IAV via HA and NA, the two most important viral 
proteins for pathogenesis. This interaction appeared to calcium dependent. It was 
also noted that rhSP-D was able to inhibit IAV interaction with the target cells leading 
to modulation of the pro-inflammatory response triggered by IAV. These results are 
consistent with those reported by extensive studies carried out by the Hartshorn 
Group (Hartshorn et al, 1998; 2006). It is clear that rhSP-D can be sufficient to offer 
protection against IAV challenge in murine models. Thus, a murine model of IAV 
infection can be generated using a range of IAV strains and the ability of rhSP-D 
intranasally treated mice can be ascertained. The viral load in the lungs and the 
pathogenesis including cytokine storm in the lungs are likely to be down-regulated by 
rhSP-D treatment. Similarly, the delta version can be tested in murine models to 
establish if the presence of 8 Gly-X-Y region is not important for the potency of the 
molecule. Further studies can be carried out to examine if virus-like particles 
conjugated to rhSP-D are likely to be a better candidate for vaccination since rhSP-D 
is good at polarising Th1 immune response. In this case, rhSP-D can act as an 
adjuvant for vaccine trials. 
In Chapter 5, it is reported that rhSP-D binds to Aspergillus fumigatus conidia in a 
dose-, calcium- and sugar-dependent manner. In addition, it is also able to enhance 
uptake by PBMCs. This is very intriguing since the current notion is that SP-D binds 
pathogens via its CRD region while the collagen region engages with calreticulin-
CD91 complex in order to trigger phagocytosis. Given the lack of knowledge about a 
putative CRD receptor that is likely to be a phagocytic receptor, it is possible that SP-
D upregulates other bonafide phagocytic receptors on the cell surface. If one 
examines the crystal structure of maltose-bound rhSP-D trimer (Shrive et al, 2003), it 
is apparent that only 2 CRD subunits are required for engaging carbohydrate ligand 
while the third subunit is available for interaction with a yet-to-be-discovered receptor 
molecule via protein-protein interaction. Thus, rhSP-D is potentially capable of acting 
as a bridging molecule between the effector immune cell and the target pathogenic 
ligand that can be virulence factors.  
The most striking information that has arisen out of this study is the ability of rhSP-D 
to have a direct fungistatic effect on the germination of A. fumigatus conidia. This is a 
very novel observation. This observation adds another layer of hierarchical 
complexity in which SP-D operates against pathogens. Since SP-D is also found in 
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the body fluids which are unlikely to be the best place for cellular infiltration, a direct 
effect (Nayak et al, 2013).  Therefore, a direct inhibitory effect on the growth of 
conidia is going to be an excellent strategy to contain the pathogen in a non-
inflammatory way. Another advantage of direct fungistatic effect of rhSP-D is a delay 
in the germination of Aspergillus conidia in the lungs would allow infiltrating immune 
cells to clear the resting conidia that are yet to germinate. It is also evident that rhSP-
D is having anti-fungal effect even on drug-resistant strains. A murine model of IPA 
or IA using drug-resistant strains should be used to ascertain if the in vivo protective 
effect of rhSP-D persists even for Aspergillus that are resistant to Amphotericin B 
and/or itraconazole. If it works, this will be a remarkable feat for a therapeutic 
protein.  
In order to understand the mechanism of direct fungistatic effect of rhSP-D, a 
transcriptome analysis of Aspergillus using RNA extracted from rhSP-D treated and 
untreated samples might shed light on the metabolic suppression of the conidia in 
the presence of rhSP-D. This can be further validated at the protein level via 
differential proteomics analysis. With respect to the potency of the two variants of 
rhSP-D, the delta molecule appears to be less effective that the Gly-X-Y containing 
molecule, suggesting that an N-terminal extension of collagen region is indeed 
advantageous towards enhancing therapeutic capacity of the rhSP-D molecule. It will 
be helpful to test the two variants of rhSP-D in murine models of IPA and ABPA in 
addition to SP-D deficient mice and compare their therapeutic potencies.  
Allergic asthma is regarded as a T-cell dependent disorder in which sensitised 
individuals develop eosinophilic airway inflammation in response to inhaled 
aeroallergens. Naïve T cells proliferate and differentiate in response to T-cell 
receptor recognition of peptide-loaded major histocompatibility complex (MHC) only 
when given co-stimulatory signals (CD80 and CD86) provided on the surface of 
professional APCs (Kishore et al, 2002). Dendritic cells (DCs) are the most efficient 
APCs having potent antigen-capturing and presenting capacity, which readily 
express co-stimulatory ligands for naïve T cells. Depending on the cytokine 
environment they encounter when maturing and on their degree of maturation, DCs 
can induce either Th1 or Th2 responses. Being resident within the airway epithelium 
(and as the only resident cell population expressing surface MHC class II molecules 
in normal, non-inflamed epithelium), airway DCs capture antigens and migrate to the 
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paracortical T cell zones of lymph node draining of the lung, where they interact with 
and sensitise naïve T cells and induce Th2-dependent airway eosinophilia 
(Medzhitov, 2008). Once allergen-specific Th2 memory cells are drawn into the lung, 
repeated allergen presentation by lung DCs may drive the persistent stimulation of 
specific memory Th2 cells and precipitate a state of chronic inflammation that 
contributes to the remodelled and hyper reactive air-ways that characterise asthma 
(Qaseem et al, 2013).  
Since DCs play a pivotal role in the pathogenesis of allergy, they may also be key 
sub-jects for therapeutic strategies/interventions. We recently investigated the 
interaction between DC and SP-D or rhSP-D. Both molecules bind to immature 
human DC in a Ca2+-dependent and carbohydrate-independent manner. Binding of 
SP-D or rhSP-D is diminished on LPS-matured DC (Binker et al, 2003). In 
concordance with these observations, immature but not mature DC express the 
putative SP-D receptor, gp340. A recently published study on bone-marrow derived 
mouse DC showed that SP-D mediated binding and uptake of Escherichia coli also 
increased antigen presentation of E. coli expressed proteins to T-cell hybridoma 
(Binker et al, 2006). Interestingly, full-length native SP-D, but not rhSP-D, enhances 
the binding and phagocytosis of Staphylococcus aureus by both DC and neutrophils. 
We are currently investigating if an interaction between SP-D and DC prevent the 
activation of the existing Th2 response but facilitate the secretion of IL-12 and the 
induction of Th1 response. These lines of investigation should help understand a 
possible link between DCs and the SP-A-and SP-D-mediated polarisation of Th 
response. IL-5 is a differentiation factor for eosinophils, IL-4 (together with IL-13) is 
an important factor for isotype switching of B lymphocytes (leading to the secretion of 
IgG1 and IgE); together they mark a characteristic Th2 response in the allergic 
immune reaction (characterized by secretion of IL-4, IL-5, IL-10 and IL-13 and 
generation of humoral immune responses) (Qaseem et al, 2013). Shifting of cellular 
responses from a predominantly Th2 to a Th1 cytokine profile, following treatment 
with SP-A, SP-D or rhSP-D, appears central to the protective mechanism since IFN-
g, a Th1 cytokine, promotes cellular immunity and normally inhibits Th2 




It appears that SP-A and SP-D are highly specialised, rather than primitive, ‘innate’ 
molecules, capable of modulating responses to foreign agents. Among the factors 
that have been shown to influence the Th1-Th2 balance, IL-12 is dominant in 
directing the development of Th1 cells that produce high amounts of IFN-. DCs 
function simultaneously as APCs and IL-12-produc-ing cells to induce the 
development of Th1 cells. Engagement of CD40 ligand (CD40L) by CD40 as well as 
CD28 by CD80 or CD86 is required for T cell priming by DCs, and IL-12 from DCs is 
a potent and obligate inducer of differentiation of IFN--producing cells in vivo. On 
the other hand, it is also considered that Th2 response is a ‘default pathway’ and 
Th2 cells would develop spontaneously in the absence of IL-12, or in the presence of 
PGE2, a product of the arachidonic acid signalling pathway, induced in allergen-
mediated cross-linking of IgE on mast cells (Wang et al, 1996; Wang et al, 1998; 
Madan et al, 2001). 
 
SP-A and SP-D have been shown to modulate bone marrow-derived mouse 
dendritic cells (DCs) (Binker et al, 2003). However these studies do not explain very 
well the in vivo data on murine models of allergy infection and inflammation. They 
also do not account for the protective effects exerted by SP-D in murine models of 
ABPA, dust mite allergy, and IPA. This is the first study that has systematically 
evaluated the modulation of immature as well as mature DCs using human cultured 
monocytes. Future studies should include testing rhSP-A and rhSP-D in an identical 
experimental setting. Knock-out mice should be tested for modulation of IL-13 
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